

From: [Financial Framework \(Supplementary Powers\) Regulations](#)
To: s22
Subject: FW: 371: Draft papers: Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024 - 24 Oct Exco [SEC=UNOFFICIAL]
Date: Tuesday, 17 September 2024 5:18:46 PM
Attachments: s42
[Draft EM - Health No. 4 \(Exco consults\) - 16 Sept 24.docx](#)
[Exco minute - Health No. 4.docx](#)

From: Exco <Exco@pmc.gov.au>
Sent: Tuesday, September 17, 2024 5:15:45 PM (UTC+10:00) Canberra, Melbourne, Sydney
To: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>; Exco <Exco@pmc.gov.au>
Subject: RE: 371: Draft papers: Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024 - 24 Oct Exco [SEC=UNOFFICIAL]

**OFFICIAL: Sensitive
Legal privilege**

Dear s22

Attached are some minor formatting edits to the EM. Your departmental number is 371. Please consider these papers cleared for signature.

Kind regards

s22

s22 | Director
Legal Information Integrity | Cabinet Division
Department of the Prime Minister and Cabinet
p. s22
Ngunnawal Country, One National Circuit Barton ACT 2600 PO Box 6500 CANBERRA ACT 2600
e. s22@pmc.gov.au w: www.pmc.gov.au

From: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>
Sent: Monday, 16 September 2024 3:33 PM
To: Exco <Exco@pmc.gov.au>
Cc: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>
Subject: 371: Draft papers: Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024 - 24 Oct Exco [SEC=OFFICIAL:Sensitive, ACCESS=Legal-Privilege]

**OFFICIAL: Sensitive
Legal Privilege**


Hi Exco team,

Please find attached draft papers relating to the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024* for your review. We don't anticipate any further changes to the instrument, which is proposed for consideration at the 24 October 2024 Exco meeting.


Grateful for your comments on the papers by Thursday, 19 September 2024.

Below is a summary on the status of the proposed measures for your reference.

Instrument	Minute Number	Status
------------	---------------	--------



Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024	371	Provided with this email
---	-----	--------------------------



Please let me know if you have any questions.

With thanks,

s22



IMPORTANT: This message, and any attachments to it, contains information that is confidential and may also be the subject of legal professional or other privilege. If you are not the intended recipient of this message, you must not review, copy, disseminate or disclose its contents to any other party or take action in reliance of any material contained within it. If you have received this message in error, please notify the sender immediately by return email informing them of the mistake and delete all copies of the message from your computer system.

Be careful with this message

External email. Do not click links or open attachments unless you recognise the sender and know the content is safe.

s42



s42



s42



s42



s42



EXPLANATORY MEMORANDUM

Minute No. **371** of 2024 – Minister for Finance

Subject - *Financial Framework (Supplementary Powers) Act 1997*
Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024

The purpose of this instrument is to provide legislative authority for the expenditure of Commonwealth funds.

The *Financial Framework (Supplementary Powers) Act 1997* (the Act) confers on the Commonwealth, in certain circumstances, powers to make arrangements under which money can be spent; or to make grants of financial assistance; and to form, or otherwise be involved in, companies. The Act applies to Ministers and the accountable authorities of non-corporate Commonwealth entities, as defined under section 12 of the *Public Governance, Performance and Accountability Act 2013*.

Section 65 of the Act provides that the Governor-General may make regulations prescribing matters required or permitted by the Act to be prescribed, or necessary or convenient to be prescribed for carrying out or giving effect to the Act.

Section 32B of the Act authorises the Commonwealth to make, vary and administer arrangements, programs and grants of financial assistance specified in the *Financial Framework (Supplementary Powers) Regulations 1997* (the Principal Regulations). Schedules 1AA and 1AB to the Principal Regulations specify the arrangements, grants and programs. The overall effect of section 32B is to provide legislative authority for Commonwealth expenditure on the arrangements, programs and grants specified in the Principal Regulations. This includes providing legislative authority for the Commonwealth to be able to enter into contracts or other arrangements for the specified programs and grants.

The *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024* (the proposed Regulations) would amend Schedule 1AB to the Principal Regulations to establish legislative authority for government spending on activities administered by the Department of Health and Aged Care.

Existing funding is allocated for the:

- Quality Use of Diagnostics Therapeutic and Pathology Program to improve the way in which health technologies, medicines and medical tests are prescribed and used (up to \$34.4 million per year from 2024-25);
- Sport and Recreation Program to support activities directed at Australia hosting major international sporting events; promote access to, and participation in, sporting or recreation activities; and support the achievement of excellence in Australia's representative athletes (\$30.0 million over six years from 2024-25 was provided to support the Legacy programs for Domestic and Pacific for Rugby World Cup events in 2027 and 2029); and
- messenger Ribonucleic Acid (mRNA) vaccines and treatments program to develop and maintain Australia's onshore capability to manufacture mRNA vaccines and products,

including by purchasing mRNA vaccines and products manufactured onshore (financial implications for this element are not for publication due to commercial-in-confidence sensitivities. It is the intention of the Australian Government to disclose the funding allocated for the program once the agreements are finalised).

In accordance with section 17 of the *Legislation Act 2003*, consultation has taken place with the department responsible for administering the spending activities. Details of the proposed Regulations and consultation undertaken with key stakeholders within the affected industry during their development are set out in the Attachment.

The Act specifies no conditions that need to be satisfied before the power to make the proposed Regulations may be exercised.

The proposed Regulations would be a legislative instrument for the purposes of the *Legislation Act 2003*.

The proposed Regulations would commence on the day after registration on the Federal Register of Legislation.

The Minute recommends that Regulations be made in the form proposed.

Authority: Section 65 of the *Financial Framework (Supplementary Powers) Act 1997*

ATTACHMENT**Details of the proposed *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*****Section 1 – Name**

This section would provide that the title of the Regulations would be the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*.

Section 2 – Commencement

This section would provide that the Regulations would commence on the day after registration on the Federal Register of Legislation.

Section 3 – Authority

This section would provide that the Regulations would be made under the *Financial Framework (Supplementary Powers) Act 1997*.

Section 4 – Schedules

This section would provide that the *Financial Framework (Supplementary Powers) Regulations 1997* would be amended as set out in the Schedule to the Regulations.

Schedule 1 – Amendments***Financial Framework (Supplementary Powers) Regulations 1997***

The Regulations would amend three table items in Part 4 of Schedule 1AB to the Principal Regulations to establish legislative authority for government spending on activities to be administered by the Department of Health and Aged Care (the department).

Amended Table item 306 – Quality Use of Diagnostic, Therapeutics and Pathology Program**Item [1] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)**

Table item 306 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Quality Use of Diagnostic, Therapeutics and Pathology (QUDTP) Program.

Item 1 would amend table item 306 by omitting “to NPS Medicine Wise” in the column headed “Objective(s)”. The amendment would reflect the QUDTP Program redesigned which resulted in the transfer of responsibility for delivery of the QUDTP from NPS MedicineWise to the department.

Item [2] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, after paragraph (d))

Item 2 would amend table item 306 by inserting “; and (e) to provide education and awareness activities, events, conferences and symposiums on the safe and appropriate use of

medicines.” in the column headed “Objective(s)” after paragraph (d). The amendment would reflect the expanded responsibility of the department to deliver targeted Quality Use of Medicines educational activities to health professions and consumers.

Item [3] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)

Item 3 would amend table item 306 by omitting the word “also” in the column headed “Objective(s)”. The effect of this technical amendment to the operational provision would be to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item [4] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, paragraph (a) (second occurring))

Item 4 would amend table item 306 by repealing and substituting paragraph “(a) for the provision of, or incidental to the provision of, pharmaceutical benefits, sickness benefits or medical services (within the meaning of paragraph 51(xxiiiA) of the Constitution); or” in the column headed “Objective(s)” at paragraph (a) (second occurring). The effect of this technical amendment to the operational provision would be to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item [5] – Part 4 of Schedule 1AB (at the end of table item 306, column headed “Objective(s)”)

Item 5 would amend table item 306 by adding “; or (c) with respect to postal, telegraphic, telephonic, and other like services (within the meaning of paragraph 51(v) of the Constitution).” in the column headed “Objective(s)”. The amendment would reflect that spending activities under the QUDTP Program are also supported by the communications power as there are activities which utilise phone and internet services to achieve the objectives of the program.

The QUDTP Program was established in 1999 to support Quality Use of Medicines (QUM) in Australia. The QUDTP Program contributes to the implementation of Australia’s National Medicines Policy (NMP) and the National Strategy for Quality Use of Medicines (NSQUM) by fostering cross sector collaboration and partnerships, collecting data, providing information, raising awareness and educating health professionals and consumers about the quality use of medicines and diagnostics.

QUM objectives must be achieved within a complex and crowded QUM ecosystem. This complexity underscores the need for the QUDTP Program to be implemented in a manner consistent with the NSQUM’s five principles: primacy of the consumer; partnership; consultative, collaborative, multi-disciplinary activity; support for existing activity; and system-based approaches.

The objectives of the QUDTP Program are to:

- improve the quality use of therapeutics, diagnostics and pathology for Australian consumers;
- improve the quality use of therapeutics, diagnostics and pathology for Australian health professionals;
- facilitate free access to information to support appropriate use of therapeutics, diagnostics and pathology; and

- support the effectiveness and efficiency of the health system.

The intended outcomes of the QUDTP Program are for:

- improved use of health technologies to optimise health outcomes for Australians, through independent, evidence-based information and education;
- improved health literacy of Australians, through education of health professionals and consumer groups;
- reduced misuse of medicines and other health technologies; and
- improved sustainability of the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS).

Following an independent review, conducted by Deloitte in July/August 2022, the Government confirmed the agreement to redesign the QUDTP Program, which resulted in responsibility for the program delivery transferred to the department, working in collaboration with the Australian Commission on Safety and Quality in Health Care (ACSQHC). The QUDTP supports the optimal use of medicines and diagnostics and enhances the ACSQHC's ability to co-ordinate and drive quality and safety improvements related to medicine and diagnostic use across the Australian health system.

The redesign also included incorporating the Quality Use in Pathology Program (QUPP) into the QUDTP Program and provide for a dedicated quality use of pathology project stream to be administered alongside two existing QUDTP streams: the Health Professional Education and the Consumer Health Literacy. The quality use of pathology project stream would support innovative pathology practice and contribute to the evidence base of the national pathology accreditation program. It is intended that the quality use of pathology project stream under the QUDTP Program would fund the same scope of activity the QUPP has traditionally supported.

The Government has consulted with relevant parties regarding the QUDTP Program's redesign, these included NPS MedicineWise, the Royal Australian College of General Practitioners (RACGP), the Pharmaceutical Society of Australia, Consumers Health Forum, the National Aboriginal Community Controlled Health Organisation (NACCHO) and the ACSQHC. NPS MedicineWise and ACSQHC were heavily involved as part of the independent review process which was completed in August 2022.

The consultation supported the program's redesign which removed NPS MedicineWise as the program delivered partner. Other stakeholders such as RACGP welcomed the opportunity to compete for the grants and other activities and NACCHO welcomed the opportunities presented in the program's redesign.

The department continues to engage with interested parties through Grant Forums and other avenues as the opportunities present and as relates to the QUDTP Program's objectives.

Amended Table item 429 – Sport and Recreation Program

Item [6] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, paragraph (b) (first occurring))

Table item 429 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Sport and Recreation Program (the Program).

Item 6 would amend table item 429 by omitting “by members of the community” in the column headed “Objective(s)” at paragraph (b) (first occurring). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities across Australia and the Pacific region.

Item [7] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(i))

Item 7 would amend table item 429 by inserting “by members of the community” before “who are”, in the column headed “Objective(s)” at subparagraph (b)(i). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community who are Indigenous Australians, children, women, non-citizens, immigrants or people with disabilities.

Item [8] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(ii))

Item 8 would amend table item 429 by inserting “by members of the community,” before “to promote” in the column headed “Objective(s)” at subparagraph (b)(ii). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to promote physical and mental health and prevent disease.

Item [9] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(iii))

Item 9 would amend table item 429 by inserting “by members of the community,” before “to eliminate” in the column headed “Objective(s)” at subparagraph (b)(iii). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to eliminate racial, cultural or ethnic discrimination and promote social cohesion within the community.

Item [10] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after subparagraph (b)(iii))

Item 10 would amend table item 429 by inserting “; or (iv) in Pacific Island countries;” in the column headed “Objective(s)” after paragraph (e). The amendment would reflect the expanded scope of the Program’s objective to promote access to, and participation in, sporting or recreation activities into the Pacific region.

Item [11] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after paragraph (e))

Item 11 would amend table item 429 by inserting “(ea) with respect to places, persons, matters or things external to Australia; or (eb) with respect to Australia’s relations with the islands of the Pacific; or” in the column headed “Objective(s)” after paragraph (e). The amendment would reflect that spending activities under the Program are also supported by the external affairs power with respect to matters or things outside the geographical limits of Australia, including matters concerning Australia’s relations with other nations.

The Program provides comprehensive legislative authority for a range of activities delivered by the department through Program 4.1: Sport and Physical Activity, which is part of Outcome 4. The Program aims to increase participation in sport and physical activity by all Australians and foster excellence in Australia's high-performance athletes. Further Australia's national interests by supporting the Australian sport sector, showcasing Australia as a premier host of major international sporting events, and developing sport policy and programs.

The amendment to table item 429 would support additional funding activities for the 2027 Men's Rugby World Cup (MRWC2027) Pacific Legacy Program and the 2029 Women's Rugby World Cup (WRWC2029) Pacific Legacy Program (both referred to as the Legacy Program).

The overall purpose of the Legacy Program would be to grow the sport of rugby and maximise health, well-being and social outcomes across Australia and the Pacific region. It is proposed to include activities involving club development, facilities, equipment and workforce support, developing states and territories, national programs, school competitions, women and girls' participation, and inclusion programs.

The Rugby World Cups 2027 and 2029 and associated Legacy Program funding are part of the Government's commitment to hosting major international sporting events in the lead-up to the Brisbane 2032 Olympic and Paralympic Games (the 'green and gold decade'). The 'green and gold decade' of major sporting events would provide a platform to showcase Australia on the global stage and inspire the next generation of healthier Australians. Hosting the MRWC2027 and WRWC2029 is projected to generate more than \$2.0 billion in economic benefits to Australia. The WRWC2029 would promote gender equality and social inclusion in sport and drive increased physical activity from women and girls.

The Pacific aspects of the Legacy Program would aim to make a lasting impact on Pacific rugby by investing in the capacity and capability of the Pacific national unions and teams. It would provide vital investment for Pacific rugby in the lead-up to the MRWC2027 and WRWC2029, resulting in more competitive Pacific national teams and stronger national unions. The Legacy Program would see Rugby Australia partner with World Rugby, Oceania Rugby, and the Pacific Unions to maximise high performance, management, well-being, and social outcomes across the Pacific region.

The department, through the Office for Sport, has consulted with the Department of Foreign Affairs and Trade and Australian Sports Commission in the design of the Legacy Program.

The Office for Sport further consulted with Rugby Australia on the development of a detailed plan for the Legacy Program, taking into consideration consultations Rugby Australia had had with World Rugby and the Pacific Unions. The consultations with Rugby Australia focused on ensuring the Legacy Program was fit for purpose and suitable to the Government's objectives. Rugby Australia has been consulting with World Rugby and the Pacific Unions on developing the detailed legacy plan for the Pacific legacy funding.

Amended Table item 531 – mRNA vaccines and treatments

Item [12] – Part 4 of Schedule 1AB (table item 531, column headed “Objective(s)”)

Table item 531 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the messenger Ribonucleic Acid (mRNA) vaccines and treatments program (the program).

Item 12 would amend table item 531 by omitting “mRNA products” and substituting “mRNA vaccines and products, including by purchasing mRNA vaccines and products manufactured onshore” in the column headed “Objective(s)”. The amendment would clarify the effect of table item 531 to establish and maintain the Moderna facility in anticipation of it manufacturing mRNA respiratory vaccines for purchase by the Commonwealth.

In the 2021-22 Budget, the Government agreed to establish an onshore end-to-end, population-scale mRNA manufacturing capability in Australia under a ten-year partnership with Moderna Australia Pty Ltd (Moderna) (the Moderna Partnership). The Moderna Partnership is supported through a Facility Establishment Agreement (FEA) that commenced in March 2022 and terminates in June 2032.

The Moderna Partnership includes the establishment of a population-scale mRNA respiratory vaccine manufacturing facility and a regional research and development centre for respiratory medicines and tropical diseases in Melbourne, Victoria. The Moderna Partnership also includes financial contribution from the Victorian Government.

The Moderna Partnership would supply mRNA respiratory vaccines and provide Australia with priority access in case of pandemics. The initiative signals the Australian Government’s support for onshore advanced technology manufacturing and sovereign capability, a commitment to pandemic readiness, and supporting Australia’s world class capabilities to develop and produce the next generation of medical technology.

The construction of the facility is currently underway and expected to be completed by December 2024. Pending successful trials, regulatory approvals by the Therapeutic Goods Administration (TGA) and Health Technology Assessments, Moderna envisages to manufacture the onshore vaccines in the first half of 2025. The Australian Government would purchase the onshore vaccines outside the National Immunisation Program as per the FEA with Moderna.

The Australian Government funding commitments under the FEA include:

- an Annual Pandemic Preparedness Facility Fee which is the annual fee paid to Moderna for the up keep of the facility and commences on the date that drug manufacturing and fill/finish facilities have TGA approval to commence manufacturing mRNA vaccines; and
- an Annual Minimum Purchase Commitments of COVID-19 vaccines, plus other respiratory vaccines should they be approved by TGA. The Commonwealth’s commitment to purchasing minimum number of vaccines for delivery in each financial year.

In establishing an onshore mRNA manufacturing capability including product fill and finish facilities in Victoria, the Commonwealth's objectives are to:

- secure onshore population-scale mRNA vaccine manufacturing capability, supply and resilience to respond to future pandemics and other health emergencies;
- provide priority access to mRNA COVID-19 vaccines and other respiratory vaccines should those vaccines obtain regulatory approval from the TGA;
- place Australia at the forefront of the development of transformative mRNA technology, which could have potential widespread applications for cancer, respiratory illnesses and other medical conditions; and
- bolster industry growth and job creation, by strengthening Australia's biopharmaceuticals sector, including through enabling potential translation and commercialisation paths for Australian-based research and development.

The overarching requirements in establishing a sovereign mRNA manufacturing capability include:

- an end-to-end onshore manufacturing solution for the production and supply of mRNA pandemic and non-pandemic vaccines, for the Australian population;
- participation in the broader mRNA ecosystem including contribution to research and development;
- non-pandemic vaccine supply agreements to procure Australia's requirement for COVID-19 vaccines, RSV, influenza and other mRNA vaccines should those vaccines be developed and approved;
- ongoing pandemic preparedness fees to secure priority access to mRNA pandemic vaccines; and
- pandemic vaccine advance purchase agreements if Moderna identifies and/or develops vaccine candidates for future pandemics.

The project was a joint Taskforce activity between the department, the Department of Industry, Science, and Resources (DISR) and the Department of Finance. Across 2020 and 2021, the following governing bodies and agencies were consulted during the project phase, up to execution of agreements in March 2022:

- state governments;
- Australian Technical Advisory Group on Immunisation (ATAGI);
- TGA;
- Pharmaceutical Advisory Committee;
- COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group;
- the Department of Foreign Affairs and Trade and the Department of the Prime Minister and Cabinet; and
- an Expert Advisory Group advising on the Approach to Market process and the Moderna proposal.

DISR lead this process, and broadly the intention to establish an onshore mRNA respiratory vaccine manufacturing capability was met with a consensus to proceed.

Beyond the implementation phase to the end of the agreements, consultation will continue with state governments, DISR, TGA, ATAGI, relevant industries and the biotechnology research sector, particularly with regard to the development of the research and development ecosystem.



MINISTER FOR FINANCE

Departmental No. 371 of 2024

Minute Paper for the Executive Council

Executive Council Meeting No.

Subject

Financial Framework (Supplementary Powers) Act 1997
Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024

Approved in Council

Recommended for the approval of Her Excellency the Governor-General in Council that she make Regulations in the attached form.

Sam Mostyn AC Governor-General

Katy Gallagher Minister for Finance

Filed in the Records of the Council

Secretary to the Executive Council

From: [Financial Framework \(Supplementary Powers\) Regulations](#)
To: s22
Subject: FW: REVISED: For AS clearance: draft Regulations and Explanatory Statement (Health Measures No. 4) - 24 Oct Exco [SEC=OFFICIAL:Sensitive, ACCESS=Legal-Privilege]
Date: Wednesday, 18 September 2024 11:59:31 AM
Attachments: [image001.png](#)

From: s22@Protected.Health.gov.au>
Sent: Wednesday, September 18, 2024 11:59:07 AM (UTC+10:00) Canberra, Melbourne, Sydney
To: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>
Cc: Constitutional Risk <Constitutional.Risk@protected.health.gov.au>; s22@Protected.Health.gov.au>
Subject: RE: REVISED: For AS clearance: draft Regulations and Explanatory Statement (Health Measures No. 4) - 24 Oct Exco [SEC=OFFICIAL:Sensitive, ACCESS=Legal-Privilege]

Hi s22

Apologies for missing yesterday's timeframe and thank you for following up. s22

s22

Thank you for providing the clean version of the Regulations. It has been cleared at the SES level.

Kind regards,

s22

Senior Lawyer – Constitutional Risk Team

Legal Advice and Legislation Branch

Legal Division | Corporate Operations Group

Australian Government, Department of Health and Aged Care

T: s22@protected.health.gov.au

Sirius Buildings s22

PO Box 9848, Canberra ACT 2601, Australia

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Please note that this email and attachments may contain confidential or legally privileged information. Please consult with the Legal Division before disclosing any part of this email, or attachment, outside the Department. If you receive this email in error, please delete it and contact the sender immediately.

From: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>

Sent: Wednesday, 18 September 2024 8:37 AM

To: s22@Protected.Health.gov.au; s22

s22 [redacted]@Protected.Health.gov.au>

Cc: Constitutional Risk <Constitutional.Risk@protected.health.gov.au>; Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>

Subject: RE: REVISED: For AS clearance: draft Regulations and Explanatory Statement (Health Measures No. 4) - 24 Oct Exco [SEC=OFFICIAL:Sensitive, ACCESS=Legal-Privilege]

**OFFICIAL: Sensitive
Legal Privilege**

Morning s22 [redacted]

Can I please have an update on the issues I raised below, ie:

- s22 [redacted];
- SES clearance on the revised Regulations; and
- s22 [redacted].

Grateful for a response this morning.

Thanks,

s22 [redacted]

From: Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>
Sent: Monday, September 16, 2024 12:39:01 PM (UTC+10:00) Canberra, Melbourne, Sydney
To: s22 [redacted]@Protected.Health.gov.au <s22 [redacted]@Protected.Health.gov.au>
Cc: s22 [redacted]@Protected.Health.gov.au <s22 [redacted]@Protected.Health.gov.au>; Constitutional Risk <Constitutional.Risk@protected.health.gov.au>; Financial Framework (Supplementary Powers) Regulations <FFSPRegs@finance.gov.au>
Subject: RE: REVISED: For AS clearance: draft Regulations and Explanatory Statement (Health Measures No. 4) - 24 Oct Exco [SEC=OFFICIAL]

OFFICIAL

Thanks s22 [redacted]

I'm comfortable with the changes made in the ES. s22 [redacted]

Can you seek SES clearance on the Regulations by cob, **Tuesday 17 September 2024.**

Finally, I note we have received signed letters for s22 [redacted] and mRNA programs from Minister Butler. s22 [redacted]


[redacted] From memory, we have agreed an extension for the letter to 16 September 2024. Please let us know if you anticipate any issue with the date.

Cheers,

s22



Duplicate content from Document 38



Subject: FW: PDMS Notification - Record Assigned : MS24-000856 Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024 [SEC=OFFICIAL:Sensitive, ACCESS=Legal-Privilege]

Attachments: MS24-000856.docx; Att A - Summary - Description of Schedule 1AB.docx; Att I - Regs - Health No. 4.DOCX; Att I1 - Exco minute - Health No. 4.docx; Att I2 - EM - Health No. 4.docx; Att I3 - ES - Health No. 4.docx; Att U - Letter to Minister Butler.docx

**OFFICIAL:Sensitive
Legal Privilege**

From: noreply@pws.gov.au <noreply@pws.gov.au>
Sent: Thursday, 3 October 2024 4:06 PM
To: Fox, Amy <Amy.Fox@finance.gov.au>; s22 @finance.gov.au; s22 @finance.gov.au
Subject: PDMS Notification - Record Assigned : MS24-000856 Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024 [SEC=OFFICIAL:Sensitive,ACCESS=Legal-privilege]

SEC=OFFICIAL:Sensitive,ACCESS=Legal-privilege

SUBJECT: Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024

This is for your Information Only as the record was CC'ed to you by s22 .

This record can be viewed via the following link: [MS24-000856](#)

s22 has assigned MS24-000856 to Parliamentary Coordinator MS with the following details of the PDR

Record Details	
<i>*please note if any of the fields below are empty, the associated field is not populated in the record</i>	
PDR Number	MS24-000856
PDR Subject	Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024
Status	Cleared
Processing Instructions	Please progress to FMO. Hard copies will be delivered to FMO tomorrow morning.
Milestones	Due for Clearance: 30/09/2024 5:00:00 PM Due to Parliamentary: 30/09/2024 5:00:00 PM

Forwarding this email without updating the user access list does not provide access to the document.

For assistance please call s22 or email pdms@finance.gov.au

This is automatically generated; please do not reply to this message.

CC Recipients:

Amy Fox (Amy.Fox@finance.gov.au)

s22 @finance.gov.au)

s22 @finance.gov.au)

SEC=OFFICIAL:Sensitive,ACCESS=Legal-privilege

OFFICIAL: Sensitive

**Amendments to the *Financial Framework (Supplementary Powers) Regulations 1997*
24 October 2024 Federal Executive Council Meeting**

Summary of requests by responsible Ministers and proposed amendments:

s22



OFFICIAL: Sensitive

OFFICIAL: Sensitive

Amended table item 531 in Part 4: mRNA vaccines and treatments		
Policy authority:	Cabinet	Description: Table item 531 establishes legislative authority for government spending on the messenger Ribonucleic Acid (mRNA) vaccines and treatments program (the program).
Funding:	s47 [REDACTED]	<p>In March 2022, the Australian Government executed a 10-year agreement with Moderna Australia Pty Ltd (Moderna) to establish a population-scale mRNA respiratory vaccine manufacturing facility and a regional research and development centre for respiratory medicines and tropical diseases in Melbourne, Victoria.</p> <p>The amendment clarifies the effect of item 531 to establish and maintain the Moderna facility in anticipation of it manufacturing mRNA respiratory vaccines for purchase by the Commonwealth.</p>
Constitutional risk:	Medium	<p>Moderna is the primary project led to establish and operate the end-to-end mRNA manufacturing facility. The construction of the facility is underway and is expected to be completed by December 2024. Pending successful trials, regulatory approvals by the Therapeutic Goods Administration (TGA) and Health Technology Assessments, Moderna envisages to manufacture the onshore vaccines in the first half of 2025.</p>
Constitutional powers:	<ul style="list-style-type: none"> External Affairs power Social welfare power Executive power and express incidental power, including the nationhood aspect 	<p>The Government has committed to the following components:</p> <ul style="list-style-type: none"> Annual Pandemic Preparedness Facility Fee, which is the annual fee paid to Moderna for the upkeep of the facility and commences on the date that drug manufacturing and fill/finish facilities have TGA approval to commence manufacturing mRNA vaccines; and Annual Minimum Purchase Commitments of COVID-19 vaccines, plus other respiratory vaccines should they be approved by TGA. The Commonwealth’s commitment to purchasing minimum number of vaccines for delivery in each financial year.



Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024

I, the Honourable Sam Mostyn AC, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following regulations.

Dated 2024

Sam Mostyn AC
Governor-General

By Her Excellency's Command

Katy Gallagher
Minister for Finance

Contents

1	Name	1
2	Commencement	1
3	Authority	1
4	Schedules	1
Schedule 1—Amendments		2
<i>Financial Framework (Supplementary Powers) Regulations 1997</i>		2

1 Name

This instrument is the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day after this instrument is registered.	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under the *Financial Framework (Supplementary Powers) Act 1997*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1 Amendments

Schedule 1—Amendments

Financial Framework (Supplementary Powers) Regulations 1997

- 1 Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)**
Omit “to NPS MedicineWise”.
- 2 Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, after paragraph (d))**
Insert:
; and (e) to provide education and awareness activities, events, conferences and symposiums on the safe and appropriate use of medicines.
- 3 Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)**
Omit “also”.
- 4 Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, paragraph (a) (second occurring))**
Repeal the paragraph, substitute:
(a) for the provision of, or incidental to the provision of, pharmaceutical benefits, sickness benefits or medical services (within the meaning of paragraph 51(xxiiiA) of the Constitution); or
- 5 Part 4 of Schedule 1AB (at the end of table item 306, column headed “Objective(s)”)**
Add:
; or (c) with respect to postal, telegraphic, telephonic, and other like services (within the meaning of paragraph 51(v) of the Constitution).
- 6 Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, paragraph (b) (first occurring))**
Omit “by members of the community”.
- 7 Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(i))**
Before “who are”, insert “by members of the community”.
- 8 Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(ii))**
Before “to promote”, insert “by members of the community,”.
- 9 Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(iii))**
Before “to eliminate”, insert “by members of the community,”.

**10 Part 4 of Schedule 1AB (table item 429, column headed
“Objective(s)”, after subparagraph (b)(iii))**

Insert:

or (iv) in Pacific Island countries;

**11 Part 4 of Schedule 1AB (table item 429, column headed
“Objective(s)”, after paragraph (e))**

Insert:

(ea) with respect to places, persons, matters or things external to Australia; or

(eb) with respect to the relations of the Commonwealth with the islands of the
Pacific; or

**12 Part 4 of Schedule 1AB (table item 531, column headed
“Objective(s)”)**

Omit “mRNA products”, substitute “mRNA vaccines and products, including by
purchasing mRNA vaccines and products manufactured onshore”.



MINISTER FOR FINANCE

Departmental No. 371 of 2024

Minute Paper for the Executive Council

Executive Council
Meeting No.

Subject

Financial Framework (Supplementary Powers) Act 1997
Financial Framework (Supplementary Powers) Amendment
(Health and Aged Care Measures No. 4) Regulations 2024

Approved in Council

Recommended for the approval of Her Excellency the
Governor-General in Council that she make Regulations in
the attached form.

.....

Sam Mostyn AC
Governor-General

Katy Gallagher
Minister for Finance

.....

Filed in the Records
of the Council

.....

Secretary to the Executive Council

EXPLANATORY MEMORANDUM

Minute No. 371 of 2024 – Minister for Finance

Subject - *Financial Framework (Supplementary Powers) Act 1997*
Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024

The purpose of this instrument is to provide legislative authority for the expenditure of Commonwealth funds.

The *Financial Framework (Supplementary Powers) Act 1997* (the Act) confers on the Commonwealth, in certain circumstances, powers to make arrangements under which money can be spent; or to make grants of financial assistance; and to form, or otherwise be involved in, companies. The Act applies to Ministers and the accountable authorities of non-corporate Commonwealth entities, as defined under section 12 of the *Public Governance, Performance and Accountability Act 2013*.

Section 65 of the Act provides that the Governor-General may make regulations prescribing matters required or permitted by the Act to be prescribed, or necessary or convenient to be prescribed for carrying out or giving effect to the Act.

Section 32B of the Act authorises the Commonwealth to make, vary and administer arrangements, programs and grants of financial assistance specified in the *Financial Framework (Supplementary Powers) Regulations 1997* (the Principal Regulations). Schedules 1AA and 1AB to the Principal Regulations specify the arrangements, grants and programs. The overall effect of section 32B is to provide legislative authority for Commonwealth expenditure on the arrangements, programs and grants specified in the Principal Regulations. This includes providing legislative authority for the Commonwealth to be able to enter into contracts or other arrangements for the specified programs and grants.

The *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024* (the proposed Regulations) would amend Schedule 1AB to the Principal Regulations to establish legislative authority for government spending on activities administered by the Department of Health and Aged Care.

Existing funding is allocated for the:

- Quality Use of Diagnostics Therapeutic and Pathology Program to improve the way in which health technologies, medicines and medical tests are prescribed and used (up to \$34.4 million per year from 2024-25);
- Sport and Recreation Program to support activities directed at Australia hosting major international sporting events; promote access to, and participation in, sporting or recreation activities; and support the achievement of excellence in Australia's representative athletes (\$30.0 million over six years from 2024-25 was provided to support the Legacy programs for Domestic and Pacific for Rugby World Cup events in 2027 and 2029); and
- messenger Ribonucleic Acid (mRNA) vaccines and treatments program to develop and maintain Australia's onshore capability to manufacture mRNA vaccines and products,

including by purchasing mRNA vaccines and products manufactured onshore (financial implications for this element are not for publication due to commercial-in-confidence sensitivities. It is the intention of the Australian Government to disclose the funding allocated for the program once the agreements are finalised).

In accordance with section 17 of the *Legislation Act 2003*, consultation has taken place with the department responsible for administering the spending activities. Details of the proposed Regulations and consultation undertaken with key stakeholders within the affected industry during their development are set out in the Attachment.

The Act specifies no conditions that need to be satisfied before the power to make the proposed Regulations may be exercised.

The proposed Regulations would be a legislative instrument for the purposes of the *Legislation Act 2003*.

The proposed Regulations would commence on the day after registration on the Federal Register of Legislation.

The Minute recommends that the Regulations be made in the form proposed.

Authority: Section 65 of the *Financial Framework (Supplementary Powers) Act 1997*

ATTACHMENT

Details of the proposed *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*

Section 1 – Name

This section would provide that the title of the Regulations would be the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*.

Section 2 – Commencement

This section would provide that the Regulations would commence on the day after registration on the Federal Register of Legislation.

Section 3 – Authority

This section would provide that the Regulations would be made under the *Financial Framework (Supplementary Powers) Act 1997*.

Section 4 – Schedules

This section would provide that the *Financial Framework (Supplementary Powers) Regulations 1997* would be amended as set out in the Schedule to the Regulations.

Schedule 1 – Amendments

Financial Framework (Supplementary Powers) Regulations 1997

The Regulations would amend three table items in Part 4 of Schedule 1AB to the Principal Regulations to establish legislative authority for government spending on activities to be administered by the Department of Health and Aged Care (the department).

Item [1] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)

Amended Table item 306 – Quality Use of Diagnostic, Therapeutics and Pathology Program

Table item 306 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Quality Use of Diagnostic, Therapeutics and Pathology (QUDTP) Program.

Item 1 would amend table item 306 by omitting “to NPS Medicine Wise” in the column headed “Objective(s)”. The amendment would reflect the redesigned QUDTP Program which resulted in the transfer of responsibility for delivery of the QUDTP from NPS MedicineWise to the department.

Item [2] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, after paragraph (d))

Item 2 would amend table item 306 by inserting “; and (e) to provide education and awareness activities, events, conferences and symposiums on the safe and appropriate use of

medicines.” in the column headed “Objective(s)” after paragraph (d). The amendment would reflect the expanded responsibility of the department to deliver targeted Quality Use of Medicines educational activities to health professions and consumers.

Item [3] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)

Item 3 would amend table item 306 by omitting the word “also” in the column headed “Objective(s)”. The effect of this technical amendment to the operational provision would be to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item [4] – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, paragraph (a) (second occurring))

Item 4 would amend table item 306 by repealing and substituting paragraph “(a) for the provision of, or incidental to the provision of, pharmaceutical benefits, sickness benefits or medical services (within the meaning of paragraph 51(xxiiiA) of the Constitution); or” in the column headed “Objective(s)” at paragraph (a) (second occurring). The effect of this technical amendment to the operational provision would be to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item [5] – Part 4 of Schedule 1AB (at the end of table item 306, column headed “Objective(s)”)

Item 5 would amend table item 306 by adding “; or (c) with respect to postal, telegraphic, telephonic, and other like services (within the meaning of paragraph 51(v) of the Constitution).” in the column headed “Objective(s)”. The amendment would reflect that spending activities under the QUDTP Program are also supported by the communications power as there are activities which utilise phone and internet services to achieve the objectives of the program.

The QUDTP Program was established in 1999 to support Quality Use of Medicines (QUM) in Australia. The QUDTP Program contributes to the implementation of Australia’s National Medicines Policy (NMP) and the National Strategy for Quality Use of Medicines (NSQUM) by fostering cross sector collaboration and partnerships, collecting data, providing information, raising awareness and educating health professionals and consumers about the quality use of medicines and diagnostics.

QUM objectives must be achieved within a complex and crowded QUM ecosystem. This complexity underscores the need for the QUDTP Program to be implemented in a manner consistent with the NSQUM’s five principles: primacy of the consumer; partnership; consultative, collaborative, multi-disciplinary activity; support for existing activity; and system-based approaches.

The objectives of the QUDTP Program are to:

- improve the quality use of therapeutics, diagnostics and pathology for Australian consumers;
- improve the quality use of therapeutics, diagnostics and pathology for Australian health professionals;
- facilitate free access to information to support appropriate use of therapeutics, diagnostics and pathology; and

- support the effectiveness and efficiency of the health system.

The intended outcomes of the QUDTP Program are for:

- improved use of health technologies to optimise health outcomes for Australians, through independent, evidence-based information and education;
- improved health literacy of Australians, through education of health professionals and consumer groups;
- reduced misuse of medicines and other health technologies; and
- improved sustainability of the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS).

Following an independent review, conducted by Deloitte in July/August 2022, the Government confirmed the agreement to redesign the QUDTP Program, which resulted in responsibility for the program delivery transferred to the department, working in collaboration with the Australian Commission on Safety and Quality in Health Care (ACSQHC). The QUDTP supports the optimal use of medicines and diagnostics and enhances the ACSQHC's ability to co-ordinate and drive quality and safety improvements related to medicine and diagnostic use across the Australian health system.

The redesign also included incorporating the Quality Use in Pathology Program (QUPP) into the QUDTP Program and provide for a dedicated quality use of pathology project stream to be administered alongside two existing QUDTP streams: the Health Professional Education and the Consumer Health Literacy. The quality use of pathology project stream would support innovative pathology practice and contribute to the evidence base of the national pathology accreditation program. It is intended that the quality use of pathology project stream under the QUDTP Program would fund the same scope of activity the QUPP has traditionally supported.

The Government has consulted with relevant parties regarding the QUDTP Program's redesign, these included NPS MedicineWise, the Royal Australian College of General Practitioners (RACGP), the Pharmaceutical Society of Australia, Consumers Health Forum, the National Aboriginal Community Controlled Health Organisation (NACCHO) and the ACSQHC. NPS MedicineWise and ACSQHC were heavily involved as part of the independent review process which was completed in August 2022.

The consultation supported the program's redesign which removed NPS MedicineWise as the program delivered partner. Other stakeholders such as RACGP welcomed the opportunity to compete for the grants and other activities and NACCHO welcomed the opportunities presented in the program's redesign.

The department continues to engage with interested parties through Grant Forums and other avenues as the opportunities present and as relates to the QUDTP Program's objectives.

Amended Table item 429 – Sport and Recreation Program

Item [6] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, paragraph (b) (first occurring))

Table item 429 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Sport and Recreation Program (the Program).

Item 6 would amend table item 429 by omitting “by members of the community” in the column headed “Objective(s)” at paragraph (b) (first occurring). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities across Australia and the Pacific region.

Item [7] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(i))

Item 7 would amend table item 429 by inserting “by members of the community” before “who are”, in the column headed “Objective(s)” at subparagraph (b)(i). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community who are Indigenous Australians, children, women, non-citizens, immigrants or people with disabilities.

Item [8] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(ii))

Item 8 would amend table item 429 by inserting “by members of the community,” before “to promote” in the column headed “Objective(s)” at subparagraph (b)(ii). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to promote physical and mental health and prevent disease.

Item [9] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(iii))

Item 9 would amend table item 429 by inserting “by members of the community,” before “to eliminate” in the column headed “Objective(s)” at subparagraph (b)(iii). The amendment would reflect the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to eliminate racial, cultural or ethnic discrimination and promote social cohesion within the community.

Item [10] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after subparagraph (b)(iii))

Item 10 would amend table item 429 by inserting “; or (iv) in Pacific Island countries;” in the column headed “Objective(s)” after paragraph (e). The amendment would reflect the expanded scope of the Program’s objective to promote access to, and participation in, sporting or recreation activities into the Pacific region.

Item [11] – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after paragraph (e))

Item 11 would amend table item 429 by inserting “(ea) with respect to places, persons, matters or things external to Australia; or (eb) with respect to Australia’s relations with the islands of the Pacific; or” in the column headed “Objective(s)” after paragraph (e). The amendment would reflect that spending activities under the Program are also supported by the external affairs power with respect to matters or things outside the geographical limits of Australia, including matters concerning Australia’s relations with other nations.

The Program provides comprehensive legislative authority for a range of activities delivered by the department through Program 4.1: Sport and Physical Activity, which is part of Outcome 4. The Program aims to increase participation in sport and physical activity by all Australians and foster excellence in Australia's high-performance athletes. Further Australia's national interests by supporting the Australian sport sector, showcasing Australia as a premier host of major international sporting events, and developing sport policy and programs.

The amendment to table item 429 would support additional funding activities for the 2027 Men's Rugby World Cup (MRWC2027) Pacific Legacy Program and the 2029 Women's Rugby World Cup (WRWC2029) Pacific Legacy Program (both referred to as the Legacy Program).

The overall purpose of the Legacy Program would be to grow the sport of rugby and maximise health, well-being and social outcomes across Australia and the Pacific region. It is proposed to include activities involving club development, facilities, equipment and workforce support, developing states and territories, national programs, school competitions, women and girls' participation, and inclusion programs.

The Rugby World Cups 2027 and 2029 and associated Legacy Program funding are part of the Government's commitment to hosting major international sporting events in the lead-up to the Brisbane 2032 Olympic and Paralympic Games (the 'green and gold decade'). The 'green and gold decade' of major sporting events would provide a platform to showcase Australia on the global stage and inspire the next generation of healthier Australians. Hosting the MRWC2027 and WRWC2029 is projected to generate more than \$2.0 billion in economic benefits to Australia. The WRWC2029 would promote gender equality and social inclusion in sport and drive increased physical activity from women and girls.

The Pacific aspects of the Legacy Program would aim to make a lasting impact on Pacific rugby by investing in the capacity and capability of the Pacific national unions and teams. It would provide vital investment for Pacific rugby in the lead-up to the MRWC2027 and WRWC2029, resulting in more competitive Pacific national teams and stronger national unions. The Legacy Program would see Rugby Australia partner with World Rugby, Oceania Rugby, and the Pacific Unions to maximise high performance, management, well-being, and social outcomes across the Pacific region.

The department, through the Office for Sport, has consulted with the Department of Foreign Affairs and Trade and Australian Sports Commission in the design of the Legacy Program. The Office for Sport further consulted with Rugby Australia on the development of a detailed plan for the Legacy Program, taking into consideration consultations Rugby Australia had had with World Rugby and the Pacific Unions. The consultations with Rugby Australia focused on ensuring the Legacy Program was fit for purpose and suitable to the Government's objectives. Rugby Australia has been consulting with World Rugby and the Pacific Unions on developing the detailed legacy plan for the Pacific legacy funding.

Amended Table item 531 – mRNA vaccines and treatments

Item [12] – Part 4 of Schedule 1AB (table item 531, column headed “Objective(s)”)

Table item 531 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the messenger Ribonucleic Acid (mRNA) vaccines and treatments program (the program).

Item 12 would amend table item 531 by omitting “mRNA products” and substituting “mRNA vaccines and products, including by purchasing mRNA vaccines and products manufactured onshore” in the column headed “Objective(s)”. The amendment would clarify the effect of table item 531 to establish and maintain the Moderna facility in anticipation of it manufacturing mRNA respiratory vaccines for purchase by the Commonwealth.

In the 2021-22 Budget, the Government agreed to establish an onshore end-to-end, population-scale mRNA manufacturing capability in Australia under a ten-year partnership with Moderna Australia Pty Ltd (Moderna) (the Moderna Partnership). The Moderna Partnership is supported through a Facility Establishment Agreement (FEA) that commenced in March 2022 and terminates in June 2032.

The Moderna Partnership includes the establishment of a population-scale mRNA respiratory vaccine manufacturing facility and a regional research and development centre for respiratory medicines and tropical diseases in Melbourne, Victoria. The Moderna Partnership also includes financial contribution from the Victorian Government.

The Moderna Partnership would supply mRNA respiratory vaccines and provide Australia with priority access in case of pandemics. The initiative signals the Australian Government’s support for onshore advanced technology manufacturing and sovereign capability, a commitment to pandemic readiness, and supporting Australia’s world class capabilities to develop and produce the next generation of medical technology.

The construction of the facility is currently underway and expected to be completed by December 2024. Pending successful trials, regulatory approvals by the Therapeutic Goods Administration (TGA) and Health Technology Assessments, Moderna envisages to manufacture the onshore vaccines in the first half of 2025. The Australian Government would purchase the onshore vaccines outside the National Immunisation Program as per the FEA with Moderna.

The Australian Government funding commitments under the FEA include:

- an Annual Pandemic Preparedness Facility Fee which is the annual fee paid to Moderna for the up keep of the facility and commences on the date that drug manufacturing and fill/finish facilities have TGA approval to commence manufacturing mRNA vaccines; and
- an Annual Minimum Purchase Commitments of COVID-19 vaccines, plus other respiratory vaccines should they be approved by TGA. The Commonwealth’s commitment to purchasing minimum number of vaccines for delivery in each financial year.

In establishing an onshore mRNA manufacturing capability including product fill and finish facilities in Victoria, the Commonwealth's objectives are to:

- secure onshore population-scale mRNA vaccine manufacturing capability, supply and resilience to respond to future pandemics and other health emergencies;
- provide priority access to mRNA COVID-19 vaccines and other respiratory vaccines should those vaccines obtain regulatory approval from the TGA;
- place Australia at the forefront of the development of transformative mRNA technology, which could have potential widespread applications for cancer, respiratory illnesses and other medical conditions; and
- bolster industry growth and job creation, by strengthening Australia's biopharmaceuticals sector, including through enabling potential translation and commercialisation paths for Australian-based research and development.

The overarching requirements in establishing a sovereign mRNA manufacturing capability include:

- an end-to-end onshore manufacturing solution for the production and supply of mRNA pandemic and non-pandemic vaccines, for the Australian population;
- participation in the broader mRNA ecosystem including contribution to research and development;
- non-pandemic vaccine supply agreements to procure Australia's requirement for COVID-19 vaccines, RSV, influenza and other mRNA vaccines should those vaccines be developed and approved;
- ongoing pandemic preparedness fees to secure priority access to mRNA pandemic vaccines; and
- pandemic vaccine advance purchase agreements if Moderna identifies and/or develops vaccine candidates for future pandemics.

The project was a joint Taskforce activity between the department, the Department of Industry, Science, and Resources (DISR) and the Department of Finance. Across 2020 and 2021, the following governing bodies and agencies were consulted during the project phase, up to execution of agreements in March 2022:

- state governments;
- Australian Technical Advisory Group on Immunisation (ATAGI);
- TGA;
- Pharmaceutical Advisory Committee;
- COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group;
- the Department of Foreign Affairs and Trade and the Department of the Prime Minister and Cabinet; and
- an Expert Advisory Group advising on the Approach to Market process and the Moderna proposal.

DISR lead this process, and broadly the intention to establish an onshore mRNA respiratory vaccine manufacturing capability was met with a consensus to proceed.

Beyond the implementation phase to the end of the agreements, consultation will continue with state governments, DISR, TGA, ATAGI, relevant industries and the biotechnology research sector, particularly with regard to the development of the research and development ecosystem.

EXPLANATORY STATEMENT

Issued by the Authority of the Minister for Finance

Financial Framework (Supplementary Powers) Act 1997

*Financial Framework (Supplementary Powers) Amendment
(Health and Aged Care Measures No. 4) Regulations 2024*

The *Financial Framework (Supplementary Powers) Act 1997* (the FFSP Act) confers on the Commonwealth, in certain circumstances, powers to make arrangements under which money can be spent; or to make grants of financial assistance; and to form, or otherwise be involved in, companies. The arrangements, grants, programs and companies (or classes of arrangements or grants in relation to which the powers are conferred) are specified in the *Financial Framework (Supplementary Powers) Regulations 1997* (the Principal Regulations). The powers in the FFSP Act to make, vary or administer arrangements or grants may be exercised on behalf of the Commonwealth by Ministers and the accountable authorities of non-corporate Commonwealth entities, as defined under section 12 of the *Public Governance, Performance and Accountability Act 2013*.

The Principal Regulations are exempt from sunseting under section 12 of the *Legislation (Exemptions and Other Matters) Regulation 2015* (item 28A). If the Principal Regulations were subject to the sunseting regime under the *Legislation Act 2003*, this would generate uncertainty about the continuing operation of existing contracts and funding agreements between the Commonwealth and third parties (particularly those extending beyond 10 years), as well as the Commonwealth's legislative authority to continue making, varying or administering arrangements, grants and programs.

Additionally, the Principal Regulations authorise a number of activities that form part of intergovernmental schemes. It would not be appropriate for the Commonwealth to unilaterally sunset an instrument that provides authority for Commonwealth funding for activities that are underpinned by an intergovernmental arrangement. To ensure that the Principal Regulations continue to reflect government priorities and remain up to date, the Principal Regulations are subject to periodic review to identify and repeal items that are redundant or no longer required.

Section 32B of the FFSP Act authorises the Commonwealth to make, vary and administer arrangements and grants specified in the Principal Regulations. Section 32B also authorises the Commonwealth to make, vary and administer arrangements for the purposes of programs specified in the Principal Regulations. Section 32D of the FFSP Act confers powers of delegation on Ministers and the accountable authorities of non-corporate Commonwealth entities, including subsection 32B(1) of the Act. Schedule 1AA and Schedule 1AB to the Principal Regulations specify the arrangements, grants and programs.

Section 65 of the FFSP Act provides that the Governor-General may make regulations prescribing matters required or permitted by the Act to be prescribed, or necessary or convenient to be prescribed for carrying out or giving effect to the Act.

The *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024* (the Regulations) amend Schedule 1AB to the Principal Regulations to establish legislative authority for Government spending on activities administered by the Department of Health and Aged Care.

Existing funding is allocated for the:

- Quality Use of Diagnostics Therapeutic and Pathology Program to improve the way in which health technologies, medicines and medical tests are prescribed and used (up to \$34.4 million per year from 2024-25);
- Sport and Recreation Program to support activities directed at Australia hosting major international sporting events; promote access to, and participation in, sporting or recreation activities; and support the achievement of excellence in Australia's representative athletes (\$30.0 million over six years from 2024-25 was provided to support the Legacy programs for Domestic and Pacific for Rugby World Cup events in 2027 (men) and 2029 (women)); and
- messenger Ribonucleic Acid (mRNA) vaccines and treatments program to develop and maintain Australia's onshore capability to manufacture mRNA vaccines and products, including by purchasing mRNA vaccines and products manufactured onshore (financial implications for this element are not for publication due to commercial-in-confidence sensitivities. It is the intention of the Australian Government to disclose the funding allocated for the program once the agreements are finalised).

Details of the Regulations are set out at [Attachment A](#). A Statement of Compatibility with Human Rights is at [Attachment B](#).

The Regulations are a legislative instrument for the purposes of the *Legislation Act 2003*.

The Regulations commence on the day after registration on the Federal Register of Legislation.

Consultation

In accordance with section 17 of the *Legislation Act 2003*, consultation has taken place with the Department of Health and Aged Care.

A regulatory impact analysis is not required as the Regulations only apply to non-corporate Commonwealth entities and do not adversely affect the private sector.

Attachment A

Details of the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*

Section 1 – Name

This section provides that the title of the Regulations is the *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024*.

Section 2 – Commencement

This section provides that the Regulations commence on the day after registration on the Federal Register of Legislation.

Section 3 – Authority

This section provides that the Regulations are made under the *Financial Framework (Supplementary Powers) Act 1997*.

Section 4 – Schedules

This section provides that the *Financial Framework (Supplementary Powers) Regulations 1997* are amended as set out in the Schedule to the Regulations.

Schedule 1 – Amendments

Financial Framework (Supplementary Powers) Regulations 1997

The items in Schedule 1 amend Schedule 1AB to the Principal Regulations to provide legislative authority for government spending on activities administered by the Department of Health and Aged Care (the department).

Item 1 – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)

Amended table item 306 – Quality Use of Diagnostic, Therapeutics and Pathology Program

Table item 306 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Quality Use of Diagnostic, Therapeutics and Pathology (QUDTP) Program.

Item 1 amends table item 306 by omitting “to NPS Medicine Wise” in the column headed “Objective(s)”. The amendment reflects the redesigned QUDTP Program which resulted in the transfer of responsibility for delivery of the QUDTP from NPS MedicineWise to the department.

Item 2 – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, after paragraph (d))

Item 2 amends table item 306 by inserting “; and (e) to provide education and awareness activities, events, conferences and symposiums on the safe and appropriate use of medicines.” in the column headed “Objective(s)” after paragraph (d). The amendment reflects the expanded responsibility of the department to deliver targeted Quality Use of Medicines educational activities to health professions and consumers.

Item 3 – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”)

Item 3 amends table item 306 by omitting the word “also” in the column headed “Objective(s)”. The effect of this technical amendment to the operational provision is to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item 4 – Part 4 of Schedule 1AB (table item 306, column headed “Objective(s)”, paragraph (a) (second occurring))

Item 4 amends table item 306 by repealing and substituting paragraph “(a) for the provision of, or incidental to the provision of, pharmaceutical benefits, sickness benefits or medical services (within the meaning of paragraph 51(xxiiiA) of the Constitution); or” in the column headed “Objective(s)” at paragraph (a) (second occurring). The effect of this technical amendment to the operational provision is to align table item 306 with the current approach to referring to constitutional heads of power in table items in Schedule 1AB.

Item 5 – Part 4 of Schedule 1AB (at the end of table item 306, column headed “Objective(s)”)

Item 5 amends table item 306 by adding “; or (c) with respect to postal, telegraphic, telephonic, and other like services (within the meaning of paragraph 51(v) of the Constitution).” in the column headed “Objective(s)”. The amendment reflects that spending activities under the QUDTP Program are also supported by the communications power as there are activities which utilise phone and internet services to achieve the objectives of the program.

The QUDTP Program was established in 1999 to support Quality Use of Medicines (QUM) in Australia. The QUDTP Program contributes to the implementation of Australia’s National Medicines Policy (NMP) and the National Strategy for Quality Use of Medicines (NSQUM) by fostering cross sector collaboration and partnerships, collecting data, providing information, raising awareness and educating health professionals and consumers about the quality use of medicines and diagnostics.

QUM objectives must be achieved within a complex and crowded QUM ecosystem. This complexity underscores the need for the QUDTP Program to be implemented in a manner consistent with the NSQUM’s five principles: primacy of the consumer; partnership; consultative, collaborative, multi-disciplinary activity; support for existing activity; and system-based approaches.

The objectives of the QUDTP Program are to:

- improve the quality use of therapeutics, diagnostics and pathology for Australian consumers;
- improve the quality use of therapeutics, diagnostics and pathology for Australian health professionals;
- facilitate free access to information to support appropriate use of therapeutics, diagnostics and pathology; and
- support the effectiveness and efficiency of the health system.

The intended outcomes of the QUDTP Program are:

- improved use of health technologies to optimise health outcomes for Australians, through independent, evidence-based information and education;
- improved health literacy of Australians, through education of health professionals and consumer groups;
- reduced misuse of medicines and other health technologies; and
- improved sustainability of the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS).

Following an independent review, conducted by Deloitte in July/August 2022, the Government confirmed the agreement to redesign the QUDTP Program, which resulted in responsibility for the program delivery transferred to the department, working in collaboration with the Australian Commission on Safety and Quality in Health Care (ACSQHC). The QUDTP supports the optimal use of medicines and diagnostics and enhances the ACSQHC's ability to co-ordinate and drive quality and safety improvements related to medicine and diagnostic use across the Australian health system.

The redesign also included incorporating the Quality Use in Pathology Program (QUPP) into the QUDTP Program and provide for a dedicated quality use of pathology project stream to be administered alongside two existing QUDTP streams: Health Professional Education and Consumer Health Literacy. The quality use of pathology project stream will support innovative pathology practice and contribute to the evidence base of the national pathology accreditation program. It is intended that the quality use of pathology project stream under the QUDTP Program will fund the same scope of activity the QUPP has traditionally supported.

Spending activities under the QUDTP Program are currently delivered by ACSQHC and the department.

Activities delivered by ACSQHC include:

- National Medicines Symposium – an annual, cross-disciplinary event bringing together leading organisations, experts, clinicians, consumers and policymakers to lead discussion on improving quality use of medicines in Australia;
- Practice Reviews (PBS/MBS Feedback Letters) – aim to deliver savings for the PBS and MBS, through targeting overused items which do not represent best practice;
- MedicineInsight – a data program, used by General Practices to improve medication management and support research and policy decisions in relation to primary care data;
- Online applications – MedicineWise, a free medicine and health management tool that assists consumers and their families or carers manage their medication, medical

conditions and provides important health information; and Doctor's Bag, a free application designed to assist Australian health professionals with medication related to the PBS Doctor's Bag during emergencies;

- QUM Stewardship and Indicator Development – supports and facilitates collaboration across the health systems, raises awareness of QUM issues. QUM indicators are to be developed in consultation with key stakeholders for integration across the health system and monitor the impact of changes related to medicines; and
- former NPS MedicineWise resources for health professionals and consumers, including websites (choosing wisely, nps.org.au, learning platform), on-line training modules, and RADAR (newsletter publication).

Activities under the department's responsibility are delivered through a range of procurement and grant processes. Procurement activities include:

- Consumer Phone Lines – 1300 Medicines Line, which accepts general medication phone enquires and is staffed by pharmacists, and Adverse Medicines Events Line, which enables consumers to log adverse events to medicines to the Therapeutic Goods Administration by phone with the support of health professionals, who can support care options for the consumer;
- Australian prescriber and support for communications relating to the PBS;
- QUM Horizon scanning, priority setting and program evaluations – horizon scanning provides an analysis of current and emerging issues, priorities and policies on quality use of medicines in Australia to inform future activities;
- National Prescribing Competencies Framework (NPCF) – describes the competencies that health professionals require to prescribe medicines judiciously, appropriately, safely and effectively in the Australian healthcare system. It is used by health professional regulation, health professionals, and those developing education and training programs to support QUM; and
- National Prescribing Curriculum – online modules aim to support student/new prescriber's confidence and capabilities to prescribe in a consumer focused context and aligned to the NPCF.

Grant activities include:

- Health Professional Educational Programs – targeted towards supporting the QUM educational needs of health professionals. The grant opportunity can also support quality use of diagnostics and pathology which leads to improved QUM outcomes. The programs support synergies across the healthcare system, leveraging the grant funding to achieve shared QUM goals through the provision of evidence-based QUM initiatives;
- Consumer Health Literacy – targeted towards improving and supporting medication health literacy for Australians. The grants can also support quality use of diagnostics and pathology which leads to improved QUM outcomes. The grants require high levels of collaboration and cooperation between relevant QUM stakeholders to achieve the intended grant outcomes; and
- The QUPP, comprising three initiatives:
 - Quality Pathology Practice to support professional practice standards that meet consumer and referral needs and provide evidence-based, best practice, quality-assured services that are safe, efficient and cost effective;
 - Quality Referrals (Requesting/Ordering) to support referral practices that are informed and facilitated by best practice professional relationships and protocols

- between referrers and providers, informed by evidence, maximise health benefits, and inform and engage consumers; and
- Quality Consumer Services to develop and improve consumer-focussed, accessible and coordinated services that promote informed choice and meet consumer needs.

Funding amount and arrangements, merits review and consultation

Funding of up to \$34.4 million annually for the item comes from Program 1.1: Safety and Quality in Health Care (available to ACSQHC), Program 2.3: Pharmaceutical Benefits and Program 2.1: Medical Benefits, which are all part of Outcome 2. Details are set out in the *Portfolio Budget Statements 2024-25, Budget Related Paper No. 1.9, Health and Aged Care Portfolio* at pages 25, 78, 80, 82, 149, 150, 154, 155.

The QUDTP Program is delivered in accordance with the Commonwealth resource management framework, including the *Public Governance, Performance and Accountability Act 2013* (the PGPA Act), the *Public Governance, Performance and Accountability Rule 2014* (PGPA Rule) and the department's Accountable Authority Instructions.

The department uses a number of procurement processes for some activities and does so in line with the *Commonwealth Procurement Rules* (CPRs). These include open tenders for the delivery of specific activities (such as Australian Prescriber, National Prescribing Curriculum), the Management Advisory Service Panel, and other panels as relevant to the activity. The department also undertakes direct sourcing where appropriate and in line with the CPRs (such as engaging in contracts with other Government entities, including ACSQHC and to fund unsolicited proposals such as the engagement of the Australian Health Practitioner Regulation Agency to deliver the National Prescribing Competencies Framework) where these have aligned to the relevant programs objectives and represent value for money.

Procurement decisions will be made in accordance with the Commonwealth resource management framework, including the PGPA Act, the PGPA Rule and the CPRs. A delegate of the Secretary of the department under the *Financial Framework (Supplementary Powers) Act 1997* (FFSP Act) will be responsible for approving Commonwealth funding provided for all procurement. The delegate is the Assistant Secretary for Pricing & PBS Policy, Technology Assessment and Access Division (except for QUPP activities) and the Assistant Secretary for Diagnostic Imaging and Pathology Branch, Medicare Benefits and Digital Health Division (for QUPP activities only). These positions are the executives responsible for policies and programs the QUDTP Program supports and have the appropriate skills and experience to understand the medical and health detail of a tender. Where required, further technical expertise is available to support their decision making, including medical officers and specialist advisors and advisory groups.

The department will provide an opportunity for suppliers and tenderers to make complaints if they wish, and to receive feedback. These complaints and inquiries can be made at any time during the procurement process, and will be handled in accordance with probity requirements. Information about the tender and the resultant contracts will be made available on AusTender (www.tenders.gov.au) once the contracts are signed. Procurement decisions will be based on value for money, including capability and capacity to deliver, and price and risk considerations.

Grant activities delivered under the QUDTP Program are run as open competitive processes in line with the *Commonwealth Grants Rules and Principles 2024* (CGRPs) to support innovation and achieving value for money. Consistent with the CGRPs, the department will develop grant opportunity guidelines where necessary and have regard to the nine key principles in administering the grant.

Grant applications are assessed against the nominated selection criteria with an assessment panel making recommendations to the decision maker. Grant opportunity guidelines and information about the grants will be made available on the GrantConnect website (<http://www.grants.gov.au>). The grants will be administered by the Community Grants Hub, which is part of the Department of Social Services.

The Minister for Health and Aged Care's delegates, the Assistant Secretary, Pricing & PBS Policy Branch, Technology Assessment & Access Division, and the Assistant Secretary for Diagnostic Imaging and Pathology Branch, Medicare Benefits and Digital Health Division are responsible for approving Commonwealth funding for grant activities. They have the appropriate skills and experience to understand the medical and health detail provided within a grant application to assess how it would meet the program's objectives.

Funding decisions made in connection with the QUDTP Program, whether through grants or procurements are not considered suitable for independent merits review, as they are decisions relating to the allocation of a finite resource, from which all potential claims for a share of the resource cannot be met. In addition, any funding that has already been allocated would be affected if the original decision was overturned. The Administrative Review Council (ARC) has recognised that it is justifiable to exclude merits review in relation to decisions of this nature (see paragraphs 4.11 to 4.19 of the guide, *What decisions should be subject to merit review?* (ARC guide)).

The remaking of a decision after entry into a contractual arrangement with a successful provider is legally complex, impractical, and could result in delays to providing services to platform users. The *Government Procurement (Judicial Review) Act 2018* enables suppliers to challenge some procurement processes for alleged breaches of certain procurement rules. This legislation might provide an additional avenue of redress (compensation or injunction) for dissatisfied or potential providers, depending on the circumstances.

Further, the right to review under section 75(v) of the Constitution and review under section 39B of the *Judiciary Act 1903* may be available. Persons affected by spending decisions would also have recourse to the Commonwealth Ombudsman where appropriate.

The Government has consulted with relevant parties regarding the QUDTP Program's redesign, these included NPS MedicineWise, the Royal Australian College of General Practitioners (RACGP), the Pharmaceutical Society of Australia, Consumers Health Forum, the National Aboriginal Community Controlled Health Organisation (NACCHO) and the ACSQHC. NPS MedicineWise and ACSQHC were heavily involved as part of the independent review process which was completed in August 2022.

The program redesign resulted in the transfer of responsibility for delivery of the QUDTP from NPS MedicineWise to the department. Other stakeholders such as RACGP welcomed the opportunity to compete for the grants and other activities and NACCHO welcomed the opportunities presented in the program's redesign.

The department continues to engage with interested parties through Grant Forums and other avenues as the opportunities present and as relates to the QUDTP Program's objectives.

Constitutional considerations

Noting that it is not a comprehensive statement of relevant constitutional considerations, the objective of the item references the following powers of the Constitution:

- the social welfare power (section 51(xxiiiA));
- the external affairs power (section 51(xxix)); and
- the communications power (section 51(v)).

Social Welfare Power

The social welfare power in section 51(xxiiiA) of the Constitution empowers the Parliament to make laws with respect to the provision of certain social welfare benefits including pharmaceutical, sickness and hospital benefits.

The QUDTP Program is directed at promoting better practice in the provision of pharmaceutical medicines under the PBS and diagnostic, therapeutic and pathology medical services provided under the MBS.

External affairs power

Section 51(xxix) of the Constitution empowers the Parliament to make laws with respect to 'external affairs'. The external affairs power supports legislation implementing Australia's international obligations under treaties to which it is a party.

Australia is a party to the *International Covenant on Economic, Social and Cultural Rights* [1976] ATS 5 (ICESCR). Article 2 provides the general obligation of States Parties to undertake steps, including the adoption of legislative measures, to achieve the full realisation of the rights recognised in the Covenant. Article 12(2)(c) requires achievement of the full realisation of the 'prevention, treatment and control of epidemic, endemic, occupational and other diseases' and Article 12(2)(d) requires 'the creation of conditions which would assure to all medical service and medical attention in the event of sickness'.

The QUDTP Program enhances the quality use of medicines and reduces adverse drug events (e.g. incorrect taking of medicines), including by ensuring information is made available about the judicious, appropriate, safe and effective use of medicines.

Communications power

Section 51(v) of the Constitution empowers the Parliament to make laws with respect to 'postal, telegraphic, telephonic and other like services'.

Aspects of the QUDTP Program utilise phone and internet services to achieve the objectives of the program.

Amended table item 429 – Sport and Recreation Program

Item 6 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, paragraph (b) (first occurring))

Table item 429 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the Sport and Recreation Program (the Program).

Item 6 amends table item 429 by omitting “by members of the community” in the column headed “Objective(s)” at paragraph (b) (first occurring). The amendment reflects the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities across Australia and the Pacific region.

Item 7 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(i))

Item 7 amends table item 429 by inserting “by members of the community” before “who are”, in the column headed “Objective(s)” at subparagraph (b)(i). The amendment reflects the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community who are Indigenous Australians, children, women, non-citizens, immigrants or people with disabilities.

Item 8 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(ii))

Item 8 amends table item 429 by inserting “by members of the community,” before “to promote” in the column headed “Objective(s)” at subparagraph (b)(ii). The amendment reflects the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to promote physical and mental health and prevent disease.

Item 9 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, subparagraph (b)(iii))

Item 9 amends table item 429 by inserting “by members of the community,” before “to eliminate” in the column headed “Objective(s)” at subparagraph (b)(iii). The amendment reflects the alignment of the Program’s objective to promote access to, and participation in, sporting or recreation activities by members of the community to eliminate racial, cultural or ethnic discrimination and promote social cohesion within the community.

Item 10 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after subparagraph (b)(iii))

Item 10 amends table item 429 by inserting “; or (iv) in Pacific Island countries;” in the column headed “Objective(s)” after paragraph (e). The amendment reflects the expanded scope of the Program’s objective to promote access to, and participation in, sporting or recreation activities into the Pacific region.

Item 11 – Part 4 of Schedule 1AB (table item 429, column headed “Objective(s)”, after paragraph (e))

Item 11 amends table item 429 by inserting new paragraphs “(ea) with respect to places, persons, matters or things external to Australia; or (eb) with respect to Australia’s relations with the islands of the Pacific; or” in the column headed “Objective(s)” after paragraph (e). The amendment reflects that spending activities under the Program are also supported by the external affairs power with respect to matters or things outside the geographical limits of Australia, including matters concerning Australia’s relations with other nations.

The Program provides legislative authority for a range of activities delivered by the department through Program 4.1: Sport and Physical Activity, which is part of Outcome 4. The Program aims to increase participation in sport and physical activity by all Australians and foster excellence in Australia’s high-performance athletes. It also aims to further Australia’s national interests by supporting the Australian sport sector, showcasing Australia as a premier host of major international sporting events, and developing sport policy and programs.

Funding under the Program supports activities across three streams:

- major international sporting events, to showcase Australia as a premier host of international sporting events through the bidding for and staging of major international sporting events in Australia;
- achieving excellence in Australia’s representative athletes, to foster and supporting excellence in Australia’s high performance or elite athletes; improve Australia’s ability to identify and develop high performance and elite athletes including para-athletes to compete internationally; enable and empower sports to achieve sustained sporting success on domestic and international sporting stages; and promote gender equality in professional sport by supporting female athletes and women in leadership in sport; and
- increase participation in sport and recreation activities, to promote participation by all Australians in sporting and recreational activities in order to improve physical and mental health and prevent disease; promote participation in sporting and recreational activities in order to increase social cohesion and eliminate racial, cultural or ethnic discrimination within the community; and increase participation in sport and recreation among targeted community groups, including Indigenous Australians, children, women, non-citizens, immigrants and people with disabilities.

Table item 429 is amended to support the 2027 Men’s Rugby World Cup (MRWC2027) Pacific Legacy Program and the 2029 Women’s Rugby World Cup (WRWC2029) Pacific Legacy Program (both referred to as the Legacy Program), which form part of the third funding stream under the Program.

The overall purpose of the Legacy Program is to develop the sport of rugby and maximise health, well-being and social outcomes across Australia and the Pacific region. It is proposed to include activities involving club development, facilities, equipment and workforce support, developing states and territories, national programs, school competitions, women and girls’ participation, and inclusion programs.

The Rugby World Cups 2027 and 2029 and associated Legacy Program funding are part of the Government's commitment to hosting major international sporting events in the lead up to the Brisbane 2032 Olympic and Paralympic Games (the 'green and gold decade'). The 'green and gold decade' of major sporting events provides a platform to showcase Australia on the global stage and inspire the next generation of healthier Australians. Hosting the MRWC2027 and WRWC2029 is projected to generate more than \$2.0 billion in economic benefits to Australia. The WRWC2029 will promote gender equality and social inclusion in sport and drive increased physical activity from women and girls.

The Pacific aspects of the Legacy Program aim to make a lasting impact on Pacific rugby by investing in the capacity and capability of the Pacific national unions and teams. It will provide vital investment for Pacific rugby in the lead-up to the MRWC2027 and WRWC2029, resulting in more competitive Pacific national teams and stronger national unions. The Legacy Program will see Rugby Australia partner with World Rugby, Oceania Rugby, and the Pacific Unions to maximise high performance, management, well-being, and social outcomes across the Pacific region.

The Pacific aspects of the Legacy Program funding is aligned with the Government's policy objectives outlined in the Major Sport Events Legacy Framework (the Framework), in particular through diplomacy and building stronger communities in the region, and is complementary to the Department of Foreign Affairs and Trade's PacificAus Sports programs.

The Framework, developed by the Australian Government, through the Office for Sport and in consultation with relevant Government agencies, provides an overview of the Australian Government policy objectives that can be achieved through hosting major sporting events.

The Framework's vision is to attract, deliver and leverage world class major sporting events to provide the greatest social, sporting and economic benefits for all Australians. The five pillars that support the vision are:

- Promoting gender equality and a more inclusive society;
- Building a healthy and connected community;
- Showcasing Australia to the world;
- Strengthening our future; and
- Achieving sporting success.

Sport is one of the most powerful and influential social institutions. Hosting a major sporting event has the potential to provide economic, social, cultural, environmental and sporting benefits to Australia and enhance Australia international reputation.

Funding amount and arrangements, merits review and consultation

Funding of \$30.0 million over six years from 2024-25 for the Legacy Program will come from Program 4.1: Sport and Physical Activity, which is part of Outcome 4. Details are set out in the *Portfolio Budget Statements 2024-25, Budget Related Paper No. 1.9, Health and Aged Care Portfolio* at page 103.

The department will provide funding for the Legacy Program to Rugby Australia as a non-competitive grant process. The grant will be administered in accordance with the Commonwealth resource management framework, including the PGPA Act, the PGPA Rule and the CGRPs.

In line with the CGRPs, the department will develop grant opportunity guidelines and will have regard to the nine key principles in administering the grant.

Grant opportunity guidelines and information about the grant will be made available on the GrantConnect website (www.grants.gov.au), and the grant will be administered by the Community Grants Hub, which is part of the Department of Social Services.

The delegate of the Secretary of the department, the Assistant Secretary, Major Events Branch will be responsible for approving Commonwealth funding provided to Rugby Australia acting in accordance with the FFSP Act. The Assistant Secretary has extensive experience in overseeing delivery of major sporting events and related legacy programs hosted in Australia, from grant development and assessment, event delivery and event evaluation.

Funding decisions in relation to the Legacy Program will not be suitable for independent merits review because the funding will be delivered through a closed non-competitive grant to Rugby Australia, as the only suitable organisation to facilitate the program. The decision for funding is not directed towards the circumstances of particular persons, but rather applies generally to the community, and is therefore considered to be unsuitable for review. This event, by its nature is unlikely to affect the interests of any one person.

Further, decisions relating to the allocation of a finite resource, from which all potential claims for a share of the resource cannot be met, have been recognised by the ARC as justifiable to exclude merits review (see paragraphs 4.11 to 4.19 of the ARC guide).

In any case, the right to review under section 75(v) of the Constitution and review under section 39B of the *Judiciary Act 1903* may be available. Persons affected by spending decisions would also have recourse to the Commonwealth Ombudsman where appropriate.

The department, through the Office for Sport, has consulted with the Department of Foreign Affairs and Trade and Australian Sports Commission in the design of the Legacy Program.

The Office for Sport further consulted with Rugby Australia on the development of a detailed plan for the Legacy Program, taking into consideration consultations Rugby Australia had had with World Rugby and the Pacific Unions. The consultations with Rugby Australia focused on ensuring the Legacy Program was fit for purpose and suitable to the Government's objectives. Rugby Australia has been consulting with World Rugby and the Pacific Unions on developing the detailed legacy plan for the Pacific legacy funding.

Constitutional considerations

Noting that it is not a comprehensive statement of relevant constitutional considerations, the objective of the amended item references the following powers of the Constitution:

- the communications power (section 51(v));
- the aliens power (section 51(xix));
- the race power (section 51(xxvi));
- the immigration power (section 51(xxvii));
- the external affairs power (section 51(xxix));
- the Pacific Islands power (section 51(xxx));
- the executive power and express incidental power (section 61 and section 51(xxxix)), including the nationhood aspect; and
- the Territories power (section 122).

Communications power

Section 51(v) of the Constitution empowers the Parliament to make laws with respect to ‘postal, telegraphic, telephonic and other like services’. The Legacy Program will assist with improvements to ICT infrastructure or may be conducted through the internet, telephone or broadcast media (such as publishing information and analysis about the Legacy Program over the internet).

Aliens power

Section 51(xix) of the Constitution empowers the Parliament to make laws with respect to ‘naturalization and aliens’. The Legacy Program aims to increase and promote participation in sport and recreation amongst different groups in Australia and in Pacific nations, including to benefit persons born outside Australia, whose parents were not Australians, and who has not been naturalised as an Australian.

Race power

Section 51(xxvi) of the Constitution empowers the Parliament to make laws with respect to ‘the people of any race for whom it is deemed necessary to make special laws’. The Legacy Program aims to increase and promote participation in sport and recreation to different groups in society, including activities specifically directed at Indigenous Australians and persons of other particular races.

Immigration power

Section 51(xxvii) of the Constitution empowers the Parliament to make laws with respect to ‘immigration and emigration’. The Legacy Program aims to increase and promote participation in sport and recreation to different groups in society, including activities specifically directed at new migrants.

External affairs power

Section 51(xxix) of the Constitution empowers the Parliament to make laws with respect to 'external affairs'.

The external affairs power supports legislation with respect to matters or things outside the geographical limits of Australia. The Pacific aspects of the Legacy Program will involve the delivery of activities to increase and promote participation in sport and recreation in the Pacific region.

The external affairs power also supports legislation with respect to matters concerning Australia's relations with other nations. The Pacific aspects of the Legacy Program aim to strengthen relations between Australia and Pacific Island countries.

The external affairs power also supports legislation implementing Australia's international obligations under treaties to which it is a party.

Convention on the Rights of the Child (CRC)

Australia is a party to the CRC [1991] ATS 4. Under Article 4, Australia is under an obligation as a party to the CRC to 'undertake all appropriate legislative, administrative, and other measures for the implementation of rights recognized' in the CRC. This includes the right under Article 24 to pursue the full implementation of 'the rights of the child to the enjoyment of the highest attainable standard of health', including by 'develop[ing] preventive health care' and 'guidance for parents'. This also includes the right under Article 31 to respect and promote the 'right of the child to participate fully in cultural and artistic life' and 'encourage the provision of appropriate and equal opportunities for cultural, artistic, recreational and leisure activity'.

The Legacy Program aims to increase and promote participation in sport and recreation to different groups in society, including children.

Convention on the Elimination of All Forms of Discrimination against Women (CEDAW)

Australia is a party to the CEDAW [1983] ATS 9. The Legacy Program is particularly relevant to Articles 2 and 10 of the CEDAW.

Article 2 requires States Parties to:

1. ...condemn discrimination against women in all its forms, agree to pursue by all appropriate means and without delay a policy of eliminating discrimination against women and, to this end, undertake...
 - (b) To adopt appropriate legislative and other measures, including sanctions where appropriate, prohibiting all discrimination against women...
 - (e) To take all appropriate measures to eliminate discrimination against women by all persons, organisation or enterprise;
 - (f) To take all appropriate measures, including legislation, to modify or abolish existing laws, regulations, customs and practices which constitute discrimination against women;

Article 10 requires States Parties to:

1. ...take all appropriate measures to eliminate discrimination against women in order to ensure to them equal rights with men in the field of education and in particular to ensure, on a basis of equality of men and women...
 - (g) The same Opportunities to participate actively in sports and physical education.

The Legacy Program aims to increase and promote participation in sport and recreation to different groups in society, including specifically to women.

Convention on the Rights of Persons with Disability (CRPD)

Australia is a party to the CRPD [2008] ATS 12. Parties to the CRPD are required to ensure and promote the full realisation of all human rights and fundamental freedoms for all persons with disabilities without discrimination of any kind on the basis of disability (Art 4(1)). Parties to the CRPD are also required to 'recognize the right of persons with disabilities to take part on an equal basis with others in cultural life' (Article 30(1)). This includes to 'enable persons with disabilities to participate on an equal basis with others in recreational, leisure and sporting activities' (Article 30(5)).

In particular, Article 30(5) requires States Parties to take appropriate measures:

- (a) To encourage and promote the participation, to the fullest extent possible, of persons with disabilities in mainstream sporting activities at all levels;
- (b) To ensure that persons with disabilities have an opportunity to organize, develop and participate in disability-specific sporting and recreational activities and, to this end, encourage the provision, on an equal basis with others, of appropriate instruction, training and resources;
- (c) To ensure that persons with disabilities have access to sporting, recreational and tourism venues;
- (d) To ensure that children with disabilities have equal access with other children to participation in play, recreation and leisure and sporting activities, including those activities in the school system;
- (e) To ensure that persons with disabilities have access to services from those involved in the organization of recreational, tourism, leisure and sporting activities.

The Legacy Program aims to increase and promote participation in sport and recreation to different groups in society, including specifically to people with disabilities.

International Covenant on Economic, Social and Cultural Rights (ICESCR)

Australia is a party to the ICESCR. Article 12(1) of the ICESCR recognises the 'right of everyone to the enjoyment of the highest attainable standard of physical and mental health'. Article 15(1) of the ICESCR recognises the 'right of everyone to take part in cultural life'. Article 2 requires each State Party to 'take steps...to the maximum of its available resources, with a view to achieving progressively the full realisation' of this right 'by all appropriate means, including particularly the adoption of legislative measures'.

The steps to be taken by States Parties to achieve full realisation of the right to health are specified in Article 12(2) and include steps necessary for:

- (a) The prevention, treatment and control of epidemic, endemic, occupational and other diseases (Article 12(2)(c)); and
- (b) The creation of conditions which would assure to all medical service and medical attention in the event of sickness (Article 12(2)(d)).

The steps to be taken by States Parties to achieve full realisation of the right to take part in cultural life are specified in Article 15 and include steps necessary for ‘full realization of this right shall include those necessary for the conservation, the development and the diffusion of science and culture’.

The Legacy Program aims to promote participation in sporting and recreational activities in order to improve physical and mental health and prevent disease. The Legacy Program also promotes participation in sporting and recreational activities in order to increase social cohesion and eliminate racial, cultural or ethnic discrimination within the community.

Pacific Islands power

Section 51(xxx) of the Constitution empowers the Parliament to make laws with respect to ‘the relations of the Commonwealth with the islands of the Pacific’. The Pacific aspects of the Legacy Program aim to strengthen relations between Australia and Pacific Island countries.

Executive power and express incidental power, including the nationhood aspect

The express incidental power in section 51(xxxix) of the Constitution empowers the Parliament to make laws with respect to matters incidental to the execution of any power vested in the Parliament, the executive or the courts by the Constitution. Section 61 of the Constitution supports activities that are peculiarly adapted to the government of a nation and cannot be carried out for the benefit of the nation otherwise than by the Commonwealth.

Aspects of the Legacy Program are aimed at reducing racial, cultural and religious intolerance and strengthening social cohesion, community harmony and cross-cultural understanding for the benefit of the nation, particularly where promoting the program can be demonstrably linked to addressing national security risks).

Territories power

Section 122 of the Constitution empowers the Parliament to ‘make laws for the government of any territory’.

The Legacy Program aims to promote participation in sporting and recreational activities in Australia, including the delivery of activities in the Territories.

Amended table item 531 – mRNA vaccines and treatments

Item 12 – Part 4 of Schedule 1AB (table item 531, column headed “Objective(s)”)

Table item 531 in Part 4 of Schedule 1AB establishes legislative authority for government spending on the messenger Ribonucleic Acid (mRNA) vaccines and treatments program (the program).

Item 12 amends table item 531 by omitting “mRNA products” and substituting “mRNA vaccines and products, including by purchasing mRNA vaccines and products manufactured onshore” in the column headed “Objective(s)”. The amendment clarifies the effect of table item 531 to establish and maintain the Moderna facility in anticipation of it manufacturing mRNA respiratory vaccines for purchase by the Commonwealth.

In the 2021-22 Budget, the Government agreed to establish an onshore end-to-end, population-scale mRNA manufacturing capability in Australia under a ten-year partnership with Moderna Australia Pty Ltd (Moderna) (the Moderna Partnership). The Moderna Partnership is supported through a Facility Establishment Agreement (FEA) that commenced in March 2022 and will terminate in June 2032.

The Moderna Partnership includes the establishment of a population-scale mRNA respiratory vaccine manufacturing facility and a regional research and development centre for respiratory medicines and tropical diseases in Melbourne, Victoria. The Moderna Partnership also includes financial contribution from the Victorian Government.

The Moderna Partnership will supply mRNA respiratory vaccines and provide Australia with priority access in case of pandemics. The initiative signals the Australian Government’s support for onshore advanced technology manufacturing and sovereign capability, a commitment to pandemic readiness, and supporting Australia’s world class capabilities to develop and produce the next generation of medical technology.

The construction of the facility is currently underway and expected to be completed by December 2024. Pending successful trials, regulatory approvals by the Therapeutic Goods Administration (TGA) and Health Technology Assessments (HTA), Moderna envisages to manufacture the onshore vaccines in the first half of 2025. The Australian Government will purchase the onshore vaccines outside the National Immunisation Program as per the FEA with Moderna.

The Australian Government funding commitments under the FEA include:

- an Annual Pandemic Preparedness Facility Fee which is the annual fee paid to Moderna for the up keep of the facility and commences on the date that drug manufacturing and fill/finish facilities have TGA approval to commence manufacturing mRNA vaccines; and
- an Annual Minimum Purchase Commitments of COVID-19 vaccines, plus other respiratory vaccines should they be approved by TGA. The Commonwealth’s commitment to purchasing minimum number of vaccines for delivery in each financial year.

The final funding amount paid to Moderna will depend on several factors including:

- determining COVID-19 needs based on recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI);
- the number of Moderna mRNA vaccines approved by the TGA;
- the results of undertaking HTA noting the onshore vaccines will not go through the Pharmaceutical Advisory Committee (PBAC) process and therefore will not be listed as designated vaccines on the National Immunisation Program (refer to section 9B of the *National Health Act 1953*); and
- the date by which the TGA will provide their Good Manufacturing Practice (GMP) license for the facility, and approve manufacturing each vaccine at the facility.

Building on the success of breakthrough COVID-19 mRNA vaccines, the Commonwealth recognises that the mRNA technology is part of the next generation in advanced health care. Onshore production of mRNA vaccines will strengthen the Commonwealth's capacity against COVID-19 and its variants, other respiratory disease vaccines including respiratory syncytial virus (RSV) and influenza, as well as future pandemics.

In establishing an onshore mRNA manufacturing capability including product fill and finish facilities in Victoria, the Commonwealth's objectives are to:

- secure onshore population-scale mRNA vaccine manufacturing capability, supply and resilience to respond to future pandemics and other health emergencies;
- provide priority access to mRNA COVID-19 vaccines and other respiratory vaccines should those vaccines obtain regulatory approval from the TGA;
- place Australia at the forefront of the development of transformative mRNA technology, which could have potential widespread applications for cancer, respiratory illnesses and other medical conditions; and
- bolster industry growth and job creation, by strengthening Australia's biopharmaceuticals sector, including through enabling potential translation and commercialisation paths for Australian-based research and development.

The overarching requirements in establishing a sovereign mRNA manufacturing capability include:

- an end-to-end onshore manufacturing solution for the production and supply of mRNA pandemic and non-pandemic vaccines, for the Australian population;
- participation in the broader mRNA ecosystem including contribution to research and development;
- non-pandemic vaccine supply agreements to procure Australia's requirement for COVID-19 vaccines, RSV, influenza and other mRNA vaccines should those vaccines be developed and approved;
- ongoing pandemic preparedness fees to secure priority access to mRNA pandemic vaccines; and
- pandemic vaccine advance purchase agreements if Moderna identifies and/or develops vaccine candidates for future pandemics.

Moderna is the primary project lead to establish and operate the end-to-end mRNA manufacturing facility. However, the Commonwealth represented by the department is the head agency for the FEA with Moderna and provides the ongoing contract management and supplier engagement. The department will also work closely with the Department of Industry, Science, and Resources (DISR) which provides policy support in relation to the research and

development ecosystem and regional hub elements; and the Department of Jobs, Skills, Industry and Regions in Victoria (through mRNA Victoria), which provides support in relation to construction of the facility and development of the regional research and development centre in Victoria.

Funding amount and arrangements, merits review and consultation

Under the FEA between Moderna and Australia for establishing onshore capability to manufacture mRNA products, procurement of vaccines is yet to occur. The procurement will be represented under sub-agreements with Moderna, which upon finalisation will provide greater clarity around the amount of funding allocated to the program.

To ensure confidentiality of commercial information in the agreements between Australia and Moderna is maintained and to ensure that disclosure of financial implications is in line with the final contract terms, it is the intention of the Australian Government to disclose the funding allocated for the program once the agreements are finalised.

The department will procure the goods and services with Moderna in accordance with applicable legislative requirements and the Commonwealth resource management framework under the PGPA Act, the PGPA Rule, the CPRs and the department's Accountable Authority Instructions.

The expenditure will be provided through an approved process, including a procurement process. In this regard, the Secretary of the department (as the relevant Accountable Authority) has made a determination under paragraph 2.6 of the CPRs to disapply Divisions 1 and 2 of the CPRs to the proposed procurement of onshore mRNA manufacturing capability and supply of mRNA vaccines and treatments for both pandemic and non-pandemic purposes and all incidental or related matters (the procurement) on the basis that it is necessary to protect human health. Accordingly, the requirement to publish the details of the proposed procurement on AusTender as set out in the CPRs will not apply. However, the department will be required to table details relating to the proposed procurement, in accordance with the *Senate Procedural Orders of Continuing Effect No. 12* (Production of Indexed Lists of Departmental and Agency Files).

Irrespective of the exemption given under paragraph 2.6 of CPRs, any procurement decisions, in particular for vaccine dose ordering, would be based on value for money, including capability and capacity to deliver, and price and risk considerations.

Vaccine purchase decisions will be made following a thorough HTA process, similar to that for the Pharmaceutical Benefits Advisory Committee. The department will make a recommendation on purchases to the Minister for Health and Aged Care, and should agreement be given, the delegate, at the Senior Executive Service (Band 2 level) who has responsibility for the oversight of the procurement will be the final decision maker. Purchase decisions will be exercised in accordance with the PGPA Act, Moderna contract, and department policies.

The department would propose to:

- execute and manage all contracts for the above services for the term of the agreements;
- work collaboratively with DISR and the supplier to meaningfully engage in ecosystem requirements to strengthen mRNA capability in Australia; and
- report on the performance and progress of the mRNA capability, and monitor expenditure on the mRNA capability.

Procurement decisions made in connection with the program are not considered suitable for independent merits review, as those decisions would relate to the allocation of a finite resource, from which all potential claims for a share of the resource could not be met. In addition, any funding that had already been allocated would be affected if the original decision was overturned. The ARC has recognised that it is justifiable to exclude merits review in relation to decisions of this nature (see paragraphs 4.11 to 4.19 of the ARC guide).

The remaking of a procurement decision after entry into a contractual arrangement with a successful provider is legally complex, impractical, and could result in delays in ensuring onshore mRNA manufacturing capability in Australia. The *Government Procurement (Judicial Review) Act 2018* enables suppliers to challenge some procurement processes for alleged breaches of certain procurement rules. This legislation might provide an additional avenue of redress (compensation or injunction) for dissatisfied providers or potential providers, depending on the circumstances.

Furthermore, procurement for onshore mRNA manufacturing is a financial policy decision with a significant public interest element. The program is a response to the COVID-19 pandemic and would enhance sovereign capability and readiness for future pandemics. Arrangements are required to be entered into to uphold public confidence in the health systems and the national vaccination programs.

The ARC has acknowledged that it is justifiable to exclude merits review in relation to decisions of this nature (see paragraph 4.34 of the ARC guide,). While it is acknowledged that reliance on this justification for the exclusion of merits review is rare (see paragraph 4.36 of the ARC guide), the context of a global pandemic is an extremely rare situation.

The project was a joint Taskforce activity between the department, DISR and the Department of Finance. Across 2020 and 2021, the following governing bodies and agencies were consulted during the project phase, up to execution of agreements in March 2022:

- state governments;
- ATAGI;
- TGA;
- PBAC;
- COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group;
- the Department of Foreign Affairs and Trade;
- the Department of the Prime Minister and Cabinet; and
- an Expert Advisory Group advising on the Approach to Market process and the Moderna proposal.

DISR lead this process, and broadly the intention to establish an onshore mRNA respiratory vaccine manufacturing capability was met with a consensus to proceed.

Beyond the implementation phase to the end of the agreements, consultation will continue with:

- state governments;
- DISR;
- TGA;
- ATAGI;
- relevant industries; and
- the biotechnology research sector, particularly with regard to the development of the research and development ecosystem.

Constitutional considerations

Noting that it is not a comprehensive statement of relevant constitutional considerations, the objective of the item references the following powers of the Constitution:

- the external affairs power (section 51(xxix));
- the social welfare power (section 51(xxiiiA)); and
- the express incidental power and the executive power (section 51(xxxix) and section 61), including the nationhood aspect.

External affairs power

Section 51(xxix) of the Constitution empowers the Parliament to make laws with respect to 'external affairs'. The external affairs power supports legislation implementing Australia's international obligations under treaties to which it is a party.

Australia has international obligations under the ICESCR. Article 12(1) of the ICESCR recognises the 'right of everyone to the enjoyment of the highest attainable standard of physical and mental health'. Article 2 requires each State Party to 'take steps...to the maximum of its available resources, with a view to achieving progressively the full realisation' of this right 'by all appropriate means, including particularly the adoption of legislative measures'.

The steps to be taken by States Parties to achieve full realisation of the right to health are specified in Article 12(2) and include steps necessary for:

- (a) The prevention, treatment and control of epidemic, endemic, occupational and other diseases (Article 12(2)(c)); and
- (b) The creation of conditions which would assure to all medical service and medical attention in the event of sickness (Article 12(2)(d)).

The Committee on Economic, Social and Cultural Rights has expressed the view these obligations require States parties to, among other matters, 'implement and enhance immunization programmes'.

The program would fund Australia's onshore mRNA manufacturing capability and the supply of mRNA vaccines and treatments for both non-pandemic and future pandemic purposes. The program would protect human health by ensuring the Commonwealth is able to act efficiently and effectively in the interests of public health to prioritise access in Australia to mRNA vaccines and treatments. This would strengthen Australia's capacity to address future pandemics and other communicable diseases.

The program would significantly enhance timely access to cutting-edge and promising vaccines and treatments in the event of a future pandemic with continued pandemic readiness being necessary for the protection of human health in Australia.

Social welfare power

The social welfare power in section 51(xxiiiA) of the Constitution empowers the Parliament to make laws with respect to the provision of certain social welfare benefits including pharmaceutical benefits, sickness and hospital benefits and medical services.

The program relates to the provision of pharmaceutical benefits and the manufacturing of vaccines and treatments in order to prevent and treat diseases and medical conditions using mRNA technology.

Executive power and express incidental power, including the nationhood aspect

The express incidental power in section 51(xxxix) of the Constitution empowers the Parliament to make laws with respect to matters incidental to the execution of any power vested in the Parliament, the executive or the courts by the Constitution. Section 61 of the Constitution supports activities that are peculiarly adapted to the government of a nation and cannot be carried out for the benefit of the nation otherwise than by the Commonwealth.

The program relates to the onshore production of mRNA vaccines and treatments, in order to enhance Australia's immunisation programs. The program would establish a domestic capacity to produce mRNA vaccines and treatments to support Australia's pandemic readiness and responses, including for the current COVID-19 pandemic, and enabling the national supply and availability of such vaccines and treatments are important matters of national significance.

Attachment B

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*

Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024

This disallowable legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

Overview of the legislative instrument

Section 32B of the *Financial Framework (Supplementary Powers) Act 1997* (the FFSP Act) authorises the Commonwealth to make, vary and administer arrangements and grants specified in the *Financial Framework (Supplementary Powers) Regulations 1997* (the Principal Regulations) and to make, vary and administer arrangements and grants for the purposes of programs specified in the Regulations. Schedule 1AA and Schedule 1AB to the Principal Regulations specify the arrangements, grants and programs. The powers in the FFSP Act to make, vary or administer arrangements or grants may be exercised on behalf of the Commonwealth by Ministers and the accountable authorities of non-corporate Commonwealth entities, as defined under section 12 of the *Public Governance, Performance and Accountability Act 2013*.

The *Financial Framework (Supplementary Powers) Amendment (Health and Aged Care Measures No. 4) Regulations 2024* (the Regulations) amend Schedule 1AB to the Principal Regulations to establish legislative authority for Government spending on activities administered by the Department of Health and Aged Care (the department).

This disallowable legislative instrument makes the following amendments to Part 4 of Schedule 1AB:

- amends table item 306 ‘Quality Use of Diagnostics, Therapeutics and Pathology Program’;
- amends table item 429 ‘Sport and Recreation Program’; and
- amends table item 531 ‘mRNA vaccines and treatments’.

Amended table item 306 – Quality Use of Diagnostics, Therapeutics and Pathology Program

The amended table item 306 establishes legislative authority for government spending on the Quality Use of Diagnostic, Therapeutics and Pathology (QUDTP) Program to reflect changes to the program design.

The QUDTP Program was established in 1999 and aimed to:

- improve the quality use of therapeutics, diagnostics and pathology for Australian consumers;
- improve the quality use of therapeutics, diagnostics and pathology for Australian health professionals;

- facilitate free access to information to support appropriate use of therapeutics, diagnostics and pathology; and
- support the effectiveness and efficiency of the health system.

The QUDTP Program was redesigned in 2022, with the subsequent arrangements operating from 1 January 2023. The redesign primarily resulted in the responsibility for delivery of the QUDTP moving from NPS MedicineWise to the department in collaboration with the Australian Commission on Safety and Quality in Health Care (ACSQHC). The QUDTP Program supports the optimal use of medicines and diagnostics and enhances the ACSQHC's ability to co-ordinate and drive quality and safety improvements related to medicine and diagnostic use across the Australian health system.

Under the QUDTP Program, the department will also deliver targeted Quality Use of Medicines educational activities for health professionals and consumers through competitive grants and procurement processes to support the optimal use of therapeutics and diagnostics.

Funding of up to \$34.4 million annually is available for the QUDTP Program.

Human rights implications

The amended table item 306 engages the following right:

- the right of everyone to the enjoyment of the highest attainable standard of physical and mental health – Article 12 of the *International Covenant on Economic, Social and Cultural Rights* (ICESCR), read with Article 2.

Right of everyone to the enjoyment of the highest attainable standard of physical and mental health

Article 2 of the ICESCR requires each State Party to take steps to the maximum of its available resources, with a view to achieving progressively the full realisation of the rights in the ICESCR by all appropriate means, including particularly the adoption of legislative measures.

Article 12(2) of the ICESCR requires that each State Party to the ICESCR takes steps to achieve the full realisation of the right shall include for:

- (a) the provision for the reduction of the stillbirth-rate and of infant mortality and for the healthy development of the child;
- (b) the improvement of all aspects of environmental and industrial hygiene;
- (c) the prevention, treatment and control of epidemic, endemic, occupational and other diseases;
- (d) the creation of conditions which would assure to all medical service and medical attention in the event of sickness.

The QUDTP Program will advance the prevention, treatment and control of health issues and optimise health outcomes for Australians, through supporting health professionals, service providers and consumers with evidenced based education and support resources.

The amended table item 306 is compatible with human rights as the ongoing delivery of the QUDTP Program promotes quality use of medicine create conditions which assure to all medical service and medical attention in the event of sickness.

Amended table item 429 – Sport and Recreation Program

The amended table item 429 establishes legislative authority for government spending for the Sport and Recreation Program (the Program), which include a range of activities undertaken by the department through Program 4.1: Sport and Physical Activity, which is part of Outcome 4.

The Program aims to increase participation in sport and physical activity by all Australians and foster excellence in Australia's high-performance athletes. It also aims to further Australia's national interests by supporting the Australian sport sector, showcasing Australia as a premier host of major international sporting events, and developing sport policy and programs.

Table item 429 is amended to support the 2027 Men's Rugby World Cup Pacific Legacy Program and the 2029 Women's Rugby World Cup Pacific Legacy Program (both referred to as the Legacy Program).

The purpose of the Legacy Program is to expand the sport of rugby and maximise health, well-being and social outcomes across Australia and the Pacific region. It is proposed to include activities involving club development, infrastructure, equipment and workforce support, developing states and territories, national programs, school competitions, women and girls' participation, and inclusion programs.

Funding of \$30.0 million over six years from 2024-25 will be available for the Legacy Program.

Human rights implications

The amended table item 429 engages the following rights:

- the right to enjoy and benefit from culture – Articles 12 and 15 of the ICESCR, read with Article 2;
- the right of persons with disabilities to participate on an equal basis in cultural life, creation, leisure and sport – Article 30 of the *Convention on the Rights of Persons with Disability* (CRPD), read with Article 4;
- the right of women to the exercise and enjoyment of human rights and fundamental freedoms, in particular in the political, social, economic and cultural fields – Article 10 of the *Convention on the Elimination of All Forms of Discrimination against Women* (CEDAW), read with Article 2; and
- the rights of every child to engage freely in cultural life and the arts, as well as playing and recreational activities appropriate to his or her age – Articles 24 and 31 of the *Convention on the Rights of the Child* (CRC), read with Article 4.

Right to enjoy and benefit from culture

Article 2(2) of the ICESCR requires States Parties to undertake to guarantee the right to culture be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status. According to the United Nations Committee on Economic, Social and Cultural Rights, the right to culture includes sports and games.

Article 12(1) recognises the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Sport and physical activity play an important role in both physical and mental wellbeing.

Article 15(1)(a) of the ICESCR recognises the right of everyone to take part in cultural life. According to the United Nations Committee on Economic, Social and Cultural Rights, the right to culture includes sports and games. This right encompasses access to culture, which includes the availability of mainstream sporting activities at all levels and sporting events hosted in Australia, in which everyone can participate.

Rights of persons with disabilities

Article 4 of the CPRD obliges each State Party to ensure and promote the full realisation of all human rights and fundamental freedoms for all persons with disabilities without discrimination of any kind on the basis of disability. This right includes elimination of discrimination in the field of employment, which includes occupations in the sport and physical activity sector.

Article 30 of the CPRD recognises the right of persons with disabilities to participate on an equal basis with others in cultural life, recreation, leisure and sport. This right encompasses the encouragement and promotion of participation, to the fullest extent possible, of persons with disabilities in mainstream sporting activities at all levels. It also encompasses access to sport, which includes the availability of sporting events (including those specifically for persons with disabilities) hosted in Australia.

Rights of women

Article 2 of the CEDAW condemns the discrimination of women in all its forms.

Article 10 of the CEDAW recognises the right of women to the same opportunities to participate in education as men. This right encompasses the encouragement and promotion of participation, to the fullest extent possible, of women in sport and physical activity education at all levels.

Rights of the child

Article 4 of the CRC obliges each State Party to undertake measures regarding economic, social and cultural rights of children to the maximum extent of their available resources. According to the United Nations Committee on Economic, Social and Cultural Rights, the right to culture includes sports and games.

Article 24 of the CRC obliges each State Party to ensure the rights of children to the highest attainable standard of health. This includes measures to combat disease and malnutrition, provide access to health education and develop preventive health care. Sport and physical activity have recognised physical and mental health benefits, and can aid in the prevention of an array of diseases.

Article 31(1) of the CRC recognises the right of every child to rest and leisure and to engage freely in cultural life and the arts, as well as playing and recreational activities appropriate to his or her age. This right encompasses the encouragement and promotion of participation, to the fullest extent possible, of children in mainstream sporting activities at all levels.

The amended table item 429 is compatible with human rights because the item will promote and protect human rights through the outcomes achieved to enhance sport and physical activity from the delivery of the Legacy Program.

Amended table item 531 – mRNA vaccines and treatments

The amended table item 531 establishes legislative authority for government spending on the messenger Ribonucleic Acid (mRNA) vaccines and treatments program (the program) to clarify the effect of item 531 to establish and maintain the Moderna facility in anticipation of it manufacturing mRNA respiratory vaccines for purchase by the Commonwealth.

In the 2021-22 Budget, the Government agreed to establish an onshore end-to-end, population-scale mRNA manufacturing capability in Australia and a regional research and development centre for respiratory medicines and tropical diseases in Melbourne, Victoria under a ten-year partnership with Moderna Australia Pty Ltd (Moderna) (the Moderna Partnership). The Moderna Partnership is supported through a Facility Establishment Agreement (FEA) that commenced in March 2022 and will terminate in June 2032.

The Moderna Partnership will supply mRNA respiratory vaccines and provide Australia with priority access in case of pandemics. The initiative signals the Australian Government's support for onshore advanced technology manufacturing and sovereign capability, a commitment to pandemic readiness, and supporting Australia's world class capabilities to develop and produce the next generation of medical technology.

The Australian Government funding commitments under the FEA include:

- an Annual Pandemic Preparedness Facility Fee which is the annual fee paid to Moderna for the up keep of the facility and commences on the date that drug manufacturing and fill/finish facilities have Therapeutic Goods Administration approval to commence manufacturing mRNA vaccines; and
- an Annual Minimum Purchase Commitments of COVID-19 vaccines, plus other respiratory vaccines should they be approved by TGA. The Commonwealth's commitment to purchasing minimum number of vaccines for delivery in each financial year.

Human rights implications

The amended table item 531 engages the following right:

- the right of everyone to the enjoyment of the highest attainable standard of physical and mental health – Article 12 of ICESCR, read with Article 2.

Right of everyone to the enjoyment of the highest attainable standard of physical and mental health

Article 2(1) of the ICESCR requires each State Party to ‘take steps... to the maximum of its available resources, with a view to achieving progressively the full realization’ of the rights recognised in the ICESCR ‘by all appropriate means, including particularly the adoption of legislative measures’.

Article 12(1) of the ICESCR recognises the ‘right of everyone to the enjoyment of the highest attainable standard of physical and mental health’.

Article 12(2)(c) requires Australia to take steps necessary for ‘the prevention, treatment and control of epidemic, endemic, occupational and other diseases’, and Article 12(2)(d) requires Australia to take steps necessary for ‘the creation of conditions which would assure to all medical service and medical attention in the event of sickness’.

The program would fund Australia’s onshore mRNA manufacturing capability, which would enable Australia to implement and enhance its immunisation/vaccination programs. mRNA technology is currently used to prevent COVID-19 and also has the potential to treat a range of other medical conditions such as influenza, cancer and human immunodeficiency virus.

The program would promote the right to health by ensuring that Australia is well prepared to prevent, treat and control diseases and other medical conditions using mRNA technology. Having mRNA manufacturing capability onshore would also ensure that Australia is not subject to potential supply and delivery issues of facilities located offshore.

Overall, the amended table item 531 would support the right of individuals to the enjoyment of the highest standard of health and further contribute to overall community health through the prevention, treatment and control of epidemic, endemic, occupational and other diseases.

Conclusion

This disallowable legislative instrument is compatible with human rights because it promotes the protection of human rights.

**Senator the Hon Katy Gallagher
Minister for Finance**



Senator the Hon Katy Gallagher

Minister for Finance
Minister for Women
Minister for the Public Service
Senator for the Australian Capital Territory

REF: MS24-000856

The Hon Mark Butler MP
Minister for Health and Aged Care
Parliament House
CANBERRA ACT 2600

Dear Minister

Thank you for your letters of 9 September 2024 seeking my agreement to amend Schedule 1AB to the *Financial Framework (Supplementary Powers) Regulations 1997* (FFSP Regulations).

I agree to your requests to amend Schedule 1AB to the FFSP Regulations to establish legislative authority for government spending relating to the Quality Use of Diagnostics, Therapeutics and Pathology Program and the messenger Ribonucleic Acid (mRNA) vaccines and treatments program, as set out in your letters.

s42

The necessary documentation will be submitted to the Governor-General for consideration at the Executive Council meeting currently scheduled for 24 October 2024. Once the matter has been considered by the Governor-General, my Department will advise your Department of the outcome.

Yours sincerely

Katy Gallagher

PROTECTED: CABINET

PDR Number: MS24-000856
Date sent to MO: 3 October 2024



Australian Government
Department of Finance

MINISTERIAL SUBMISSION

Copies to:

Secretary

Mr Williamson

Ms Patterson

Mr Windeyer

Ms Fox

Mr Webster

Ms Harmer

Mr Sorbello

Ms Cole

Ms Carroll

Ms Tran

Minister for Finance

Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024

Minister's action due by: 15 October 2024, to enable documentation to be submitted by the cut-off date for the Federal Executive Council (ExCo) meeting scheduled for 24 October 2024.

Recommendations:

That you:

- i. **agree** to request that the Governor-General make 11 regulations to amend the *Financial Framework (Supplementary Powers) Regulations 1997* (the FFSP Regulations) as outlined at Attachment A;

AGREED / NOT AGREED / PLEASE DISCUSS

s22

NOTED / PLEASE DISCUSS

s42

NOTED / PLEASE DISCUSS

- iv. **sign**, but do not date, the proposed regulations at Attachments B to L;

SIGNED / PLEASE DISCUSS

- v. **sign**, but do not date, the Executive Council Minutes for each of the proposed regulations at Attachments B1 to L1;

SIGNED / PLEASE DISCUSS

- vi. **initial** the bottom right-hand corner of each page of the Explanatory Memoranda for each of the proposed regulations at Attachments B2 to L2;

INITIALLED / PLEASE DISCUSS

- vii. **approve** the release of the Explanatory Statements for each of the proposed regulations at Attachments B3 to L3;

APPROVED / NOT APPROVED / PLEASE DISCUSS

PROTECTED: CABINET

PROTECTED: CABINET

s22



APPROVED / NOT APPROVED / PLEASE DISCUSS

- ix. **sign** the reply letters to the responsible Ministers at Attachments N to X.

SIGNED / PLEASE DISCUSS

/ /

Katy Gallagher

Key Issues:

Schedule 1AB amendments to the FFSP Regulations

1. Requests have been received from the following Ministers (Attachment Y) for amendments to Schedule 1AB to the FFSP Regulations to establish legislative authority for 19 pending activities in their portfolios:

s22



- vii. Minister for Health and Aged Care, the Hon Mark Butler MP (2 items);

s22



PROTECTED: CABINET

PROTECTED: CABINET

s22



4. A summary of the proposed amendments to be considered at the 24 October 2024 ExCo meeting is included in Attachment A.

s42



8. Subject to your approval, all proposed regulations will be submitted for consideration by the Governor-General at the ExCo meeting scheduled for 24 October 2024.

Senate Standing Committee for the Scrutiny of Delegated Legislation (the Committee)

s22



PROTECTED: CABINET

PROTECTED: CABINET

Financial Implications:

14. Funding details for the Schedule 1AB items in the proposed regulations are set out at Attachment A.

Consultation:

15. Budget Group, Commercial Group, the responsible entities, the Office of Constitutional Law in the Attorney-General's Department and the Executive Council Secretariat were consulted.

Attachments:

Att A – Summary of the items contained in each of the regulations

Att B to L – Proposed regulations

Att B1 to L1 – Executive Council Minute Papers for each of the regulations

Att B2 to L2 – Explanatory Memoranda for each of the regulations

Att B3 to L3 – Explanatory Statements for each of the regulations

Att M – Replacement Explanatory Statement to the Finance Regulations

Att N to X – Letters to responsible Ministers, approving proposed Schedule 1AB amendments

Att Y – Letters from responsible Ministers requesting approval for amendments

Approved for electronic transmission

§22

A/g Assistant Secretary
Financial Management Branch
Financial Analysis, Reporting and Management Division

§22

Contact Officer:

§22

Job Title/Level:

Director/EL2

Telephone:

§22

PDR Number

MS24-000856

PROTECTED: CABINET

Subject: FW: PDMS Notification - Record Assigned : MS24-000856 Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024 [SEC=PROTECTED, CAVEAT=SH:CABINET]

Attachments: MS24-000856 - MF signed.pdf

From: noreply@pws.gov.au <noreply@pws.gov.au>
Sent: Thursday, 10 October 2024 5:24 PM
To: s22 @finance.gov.au; s22 @finance.gov.au; s22 @finance.gov.au; s22 @finance.gov.au; s22 @finance.gov.au; s22 @finance.gov.au; s22 @finance.gov.au
Subject: PDMS Notification - Record Assigned : MS24-000856 Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024 [SEC=PROTECTED,CAVEAT=SH:CABINET]

SEC=PROTECTED,CAVEAT=SH:CABINET

SUBJECT: Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024

This is for your Information Only as the record was CC'ed to you by s22

This record can be viewed via the following link: [MS24-000856](#)

s22 has assigned MS24-000856 to Parliamentary Coordinator MS with the following details of the PDR

Record Details	
<i>*please note if any of the fields below are empty, the associated field is not populated in the record</i>	
PDR Number	MS24-000856
PDR Subject	Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024
Status	Ready For Publication
Processing Instructions	Signed by Minister. Letters dispatched from FMO via email. Hard copies of ExCo papers retained in DLO safe.
Milestones	Due for Clearance: 30/09/2024 5:00:00 PM Due to Parliamentary: 30/09/2024 5:00:00 PM

Forwarding this email without updating the user access list does not provide access to the document.

For assistance please call s22 or email pdms@finance.gov.au

This is automatically generated; please do not reply to this message.

CC Recipients:

s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)
s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)
s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)
s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)
s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)
s22 [REDACTED] [@finance.gov.au](mailto:[REDACTED]@finance.gov.au)

SEC=PROTECTED,CAVEAT=SH:CABINET

PROTECTED: CABINET

PDR Number: MS24-000856
Date sent to MO: 3 October 2024



Australian Government
Department of Finance

MINISTERIAL SUBMISSION

Copies to:
Secretary
Mr Williamson
Ms Patterson
Mr Windeyer
Ms Fox
Mr Webster
Ms Harmer
Mr Sorbello
Ms Cole
Ms Carroll
Ms Tran

Minister for Finance

Financial Framework (Supplementary Powers) Regulations 1997 – Schedule 1AB – various portfolios – Federal Executive Council Meeting on 24 October 2024

Minister's action due by: 15 October 2024, to enable documentation to be submitted by the cut-off date for the Federal Executive Council (ExCo) meeting scheduled for 24 October 2024.

Recommendations:

That you:

- i. **agree** to request that the Governor-General make 11 regulations to amend the *Financial Framework (Supplementary Powers) Regulations 1997* (the FFSP Regulations) as outlined at Attachment A;

AGREED / NOT AGREED / PLEASE DISCUSS

s22

NOTED / PLEASE DISCUSS

s42

NOTED / PLEASE DISCUSS

- iv. **sign**, but do not date, the proposed regulations at Attachments B to L;

SIGNED / PLEASE DISCUSS

- v. **sign**, but do not date, the Executive Council Minutes for each of the proposed regulations at Attachments B1 to L1;

SIGNED / PLEASE DISCUSS

- vi. **initial** the bottom right-hand corner of each page of the Explanatory Memoranda for each of the proposed regulations at Attachments B2 to L2;

INITIALLED / PLEASE DISCUSS

- vii. **approve** the release of the Explanatory Statements for each of the proposed regulations at Attachments B3 to L3;

APPROVED / NOT APPROVED / PLEASE DISCUSS

PROTECTED: CABINET

s22



APPROVED / NOT APPROVED / PLEASE DISCUSS

ix. **sign** the reply letters to the responsible Ministers at Attachments N to X.

SIGNED / PLEASE DISCUSS

Katy Gallagher 8/10/24

Katy Gallagher

Key Issues:

Schedule 1AB amendments to the FFSP Regulations

1. Requests have been received from the following Ministers (Attachment Y) for amendments to Schedule 1AB to the FFSP Regulations to establish legislative authority for 19 spending activities in their portfolios:

s22



vii. Minister for Health and Aged Care, the Hon Mark Butler MP (2 items);

s22



PROTECTED: CABINET

s22



4. A summary of the proposed amendments to be considered at the 24 October 2024 ExCo meeting is included in Attachment A.

s42



8. Subject to your approval, all proposed regulations will be submitted for consideration by the Governor-General at the ExCo meeting scheduled for 24 October 2024.

s22



PROTECTED: CABINET

PROTECTED: CABINET

Financial Implications:

14. Funding details for the Schedule 1AB items in the proposed regulations are set out at Attachment A.

Consultation:

15. Budget Group, Commercial Group, the responsible entities, the Office of Constitutional Law in the Attorney-General's Department and the Executive Council Secretariat were consulted.

Attachments:

Att A – Summary of the items contained in each of the regulations

Att B to L – Proposed regulations

Att B1 to L1 – Executive Council Minute Papers for each of the regulations

Att B2 to L2 – Explanatory Memoranda for each of the regulations

Att B3 to L3 – Explanatory Statements for each of the regulations

Att M – Replacement Explanatory Statement to the Finance Regulations

Att N to X – Letters to responsible Ministers, approving proposed Schedule 1AB amendments

Att Y – Letters from responsible Ministers requesting approval for amendments

Approved for electronic transmission

s22

A/g Assistant Secretary
Financial Management Branch
Financial Analysis, Reporting and Management Division

s22

Contact Officer:

s22

Job Title/Level:

Director/EL2

Telephone:

s22

PDR Number

MS24-000856